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ABSTRACT 
Malaria remains a global health problem, and though international efforts for treatment and eradication 
have made some headway, the emergence of drug-resistant parasites threatens this progress.  
Antimalarial therapeutics acting via novel mechanisms are urgently required. P. falciparum M1 and 
M17 are neutral aminopeptidases which are essential for parasite growth and development.  Previous 
work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and 
revealed further regions within the protease S1 pockets that could be exploited in the development of 
ligands with improved inhibitory activity.  Herein, we report the structure-based design and synthesis 
of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-
M17.  Furthermore, the developed compounds potently inhibit Pf growth in culture, including the 
multi-drug resistant strain Dd2.  The ongoing development of dual PfA-M1/PfA-M17 inhibitors 
continues to be an attractive strategy for the design of novel antimalarial therapeutics. 
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1. Introduction 
Malaria is a parasitic disease that kills over half a million people each year, posing a huge burden to 
public health [1].  Almost half of the global population, particularly those living in sub-Saharan Africa 
and South-east Asia, remain vulnerable to malaria [1].  The disease is caused by five parasites of the 
genus Plasmodium, with Plasmodium falciparum (Pf) the most virulent.  Alarmingly, Pf has developed 
widespread resistance to commonly used antimalarials such as chloroquine, mefloquine, 
pyrimethamine, and sulfadoxine, and further resistance to the artemisinins, our last line of defense, has 
emerged in five countries of the Greater Mekong subregion (Cambodia, Thailand, Myanmar, Vietnam 
and Laos) [2].  If we are to prevent a resurgence of malaria, new therapeutics of diverse chemistry and 
different mechanisms of action are urgently required. 
Many of the clinical symptoms of malaria develop during the erythrocytic stage of infection.  
During this stage, multiple metabolic pathways are initiated within the parasites, which present a wide 
range of potential drug targets.  Among the essential metabolic pathways that occur within 
erythrocytes, is hemoglobin digestion; host hemoglobin is degraded into free amino acids that are 
absolutely required for parasite survival [3, 4].  Interference with this pathway is therefore an attractive 
strategy for the development of novel antimalarial compounds.  The final stage of this process is 
mediated by PfA-M1 [5] as well as several other metalloaminopeptidases (MAPs) that are proposed to 
work in concert to remove of the N-terminal amino acid residue from peptide fragments [6-8]. 
Two of the neutral, zinc-dependent metalloaminopeptidases from Pf, PfA-M1 and PfA-M17, are 
essential for parasite survival, and selective inhibition of either enzyme is lethal for parasites in vitro 
[5].  Further, in vivo studies have shown that inhibition of PfA-M1 and PfA-M17 controls Plasmodium 
chabaudi chabaudi murine models of malaria [9-11].  Both enzymes are therefore validated 
antimalarial therapeutic targets.  PfA-M1 and PfA-M17 are from different enzyme families, and have 
very different structural arrangements.  PfA-M1 is a monomeric protein of 1085 amino acids in length 
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(Supp. Fig. 1A).  Cleavage of an N-terminal extension (residues 1-194) forms the proteolytically active 
species that consists of four domains (residues 195-1085).  PfA-M17 is a hexamer composed of six 
identical two-domain subunits (Supp. Fig. 1B) [9, 12]. The active site of both enzymes is located 
within domain II, the catalytic domain.  The active site of PfA-M1 is enclosed deep within the catalytic 
domain and is accessed by putative substrate entry and exit channels [9].  In contrast, the six active 
sites of PfA-M17 are located on the edge of the catalytic domain, and exposed to solvent in the interior 
cavity of the hexameric assembly [12].  Despite these major differences between PfA-M1 and PfA-
M17, the enzymes share similar architecture within the active sites (Fig. 1A and 1B).  Both enzymes 
possess S1 and S1’ pockets (to accommodate P1 and P1’ residues of the peptide substrates), and 
contain catalytic zinc ion/s at the junction of the two sites (Fig. 1A and 1B).  These similarities 
prompted suggestions that a single compound capable of inhibiting both enzymes could be developed 
[12].  A drug that can effectively inhibit more than one target could potentially slow the emergence of 
drug resistance parasites.  PfA-M1 possesses one catalytic zinc ion (Zn2+), whereas PfA-M17 has two 
Zn2+ and a catalytic carbonate atom.  Previous inhibition studies show that cross inhibition of PfA-
M1/PfA-M17 is achievable by targeting these catalytic zinc ion/s [9, 10, 12-15], and led us to develop 
((4-(1H-pyrazol-1-yl)phenyl)(amino)methyl)phosphonic acid (1) (Fig. 1C) (PfA-M1 Ki = 104 µM and 
PfA-M17 Ki = 0.011 µM), which binds within the S1 pocket of both enzymes [16].  However, 
differences in the compound binding profiles of the enzymes meant that compound elaboration tended 
toward improved inhibition of one enzyme target at the expense of the other.  
We have recently developed the first inhibitor series capable of potent dual inhibition of both PfA-
M1 and PfA-M17, by introducing a hydroxamic acid moiety as a tighter zinc-binding group (ZBG) and 
exploring the S1’ pockets [17].  Two compounds were characterized as potent dual inhibitors of PfA-
M1 and PfA-M17: tert-butyl (1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)carbamate 
(2) and N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (3) (Fig. 1C).  
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Both compounds bind the catalytic zinc ion/s through the hydroxamic acid moiety, and prevent growth 
of Pf-3D7 parasites (IC50 of 2 = 783 nM; IC50 of 3 = 227 nM) with no observable human cell 
cytotoxicity [17].  
Hydroxamic acid and hydroxamate-containing compounds have previously been investigated as 
potential antimalarials.  The search for PfA-M1 inhibitors identified a malono-hydroxamic druggable 
hit [14, 18].  Chemical modification of the compound led to the discovery of BDM14471, a selective 
inhibitor of PfA-M1 [14].  The compound showed only moderate anti-parasitic activity, but in vivo 
distribution studies revealed the compound was able to reach the digestive vacuole in blood-stage 
parasites [13].  The hydroxamate-containing compound CHR-2863 is a potent PfA-M17 and moderate 
PfA-M1 inhibitor.  Excitingly, this compound was shown to be orally bioavailable and efficacious in a 
murine model of malaria [11]. 
In the present study, we aimed to improve our hydroxamic acid series as dual inhibitors of PfA-M1 
and PfA-M17 and improve their Pf parasiticidal activity.  To achieve this, we selected the two 
optimized S1’ binding moieties identified in our previous work; the N-Boc group of 2 and N-pivaloyl 
group of 3, and using them as ‘anchors’ explored the S1 pocket with a range of substituted-phenyl and 
heteroaromatic rings.  One of these series, the N-(2-(hydroxyamino)-2-oxoethyl)pivalamides, showed 
superior dual enzyme inhibitory activity compared to other PfA-M1 and PfA-M17 inhibitors, and 
resulted in greater inhibition of Pf growth in culture, including the multi-drug resistant strain Dd2.  As 
such, the inhibitors described herein represent promising lead compounds for further development. 
 
2. Results and discussion 
The 4-(1H-pyrazol-1-yl)phenyl framework of 2 and 3 was originally selected by optimization of 
PfA-M1 and PfA-M17 inhibitor series which coordinated the catalytic Zn2+ ion/s through a phosphonic 
acid moiety [16].  By exchanging the phosphonate zinc binding group for a hydroxamic acid, the 
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binding position of the 4-(1H-pyrazol-1-yl)phenyl scaffold within the S1 pocket shifted considerably 
[17].  This provided us with an avenue to build into the S1’ pocket with short aliphatic groups and 
substituted-phenyl moieties, which identified the tert-butyl group as the ideal substituent to satisfy both 
the larger PfA-M17 S1’ pocket while remaining bound within the smaller PfA-M1 S1’ pocket.  
However, the observed shift of the inhibitor scaffold indicated that further optimization of this region 
into the S1 pockets of both enzymes was necessary.  Therefore, in order to probe the S1 pocket, we 
chose to make two compound series based on tert-butyl-containing N-Boc and N-pivaloyl ‘anchors’ in 
the S1’ pocket, with which we determined detailed SAR based on enzyme inhibitory activities and X-
ray crystal structures. 
2.1 Chemistry 
Analogues of phenylglycine derivatives 2 and 3 were synthesized in which the pyrazole moiety was 
replaced with a variety of aromatic rings.  The hydroxamic acid analogues were prepared by a facile 
four-step synthesis shown in Scheme 1.  In this way, 2-amino-2-(4-bromophenyl)acetic acid (4b) or 2-
amino-3-(4-bromophenyl)propanoic acid (4d) were efficiently elaborated to provide a number of 
derivatives in good overall yields. 
Access to the target derivatives of 2, bearing pyrazole ring-replacements was achieved from 
commercially available 4b (Scheme 1).  This reagent proved to be a highly useful starting point, 
allowing installation of a number of aromatic moieties through parallel Suzuki chemistry.  In addition, 
we considered the N-Boc-protected hydroxamic acid derivative 9b to be a valid analogue in its own 
right.  The hydrophobic nature of the bromo group makes it a potential surrogate for an aromatic ring.  
Indeed, Weik and co-workers noted that non-classical bioisosteric replacement of a biphenyl moiety 
with a bromophenyl group in their series of peptidomimetic protease inhibitors gave comparable 
activity in the inhibition assay [19].  N-Boc protection of 4b was achieved in high yield following a 
procedure based on the protection of the homologous phenylalanine [20].  Subsequent conversion to the 
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desired hydroxamic acid derivative 9b proceeded smoothly in good yield using the previously 
described CDI-mediated activation method [17]. 
The remaining aryl derivatives were synthesized by conversion of 4b to the corresponding α-amino 
ester using previously described esterification conditions [17].  The crude product then underwent N-
Boc protection to give 5b in quantitative yield over two steps.  Parallel Suzuki coupling of 5b with a 
number of aromatic boronic acid or boronate ester partners, in the presence of PdCl2(PPh3)2 at 100 °C 
in degassed 1M Na2CO3 (aq)/THF readily afforded the desired 4-arylphenyl compounds 7a-p in 
generally good to excellent yield.  Only coupling with 2-cyanophenylboronic acid proved difficult, 
affording the desired product in low yield (18%).  Final conversion to the target hydroxamic acids 9f-u 
was successful with the exception of the nitrile containing derivatives. In the case of the 2-cyanophenyl 
derivative, no desired product was recoverable from the reaction mixture.  In contrast, LC-MS analysis 
of the reactions containing 3- and 4-cyanophenyl derivatives 7m-n indicated conversion to the 
corresponding hydroxamic acid after 1 hour.  After overnight stirring, aminolysis of the ester to the 
hydroxamic acid was complete, however additional attack on the nitrile groups had also occurred.  The 
isolated compounds 9r-s bore amidoxime groups in place of the nitrile groups, and proved difficult to 
purify, though inhibitory activity at PfA-M1/PfA-M17 of these unexpected analogues was still 
evaluated (Table 1).  The transformation of arylnitriles to arylamidoximes under similar conditions has 
been previously investigated [21]. 
The N-pivaloyl analogues were important target compounds that possess the tert-butyl ‘anchor’ 
optimal for binding to the S1’ pocket.  Additionally, the N-pivaloyl moiety is expected to impart better 
metabolic stability as replacement of the more labile carbamate with an amide group reduces the 
potential for hydrolysis to the free amine, which is significantly less potent [17].  Most reactions used 
for the synthesis of the N-Boc derivatives were similarly applied for the preparation of the N-pivaloyl 
analogues.  Compound 4b was esterified and subsequently reacted with Et3N and pivaloyl chloride in 
DCM at room temperature to afford compound 6b in excellent yield (94%) over 2 steps.  The Suzuki 
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reaction was again used to incorporate an additional aromatic ring, to give compounds 8a-q.  
Conversion of the methyl esters to the corresponding hydroxamic acids proceeded smoothly, affording 
the final compounds 10f-v in excellent yields.  The transformation of the nitrile moieties to amidoxime 
groups, which was previously observed for the N-Boc series, was again observed for the corresponding 
members of the N-pivaloyl series (analogues 10s and 10t). 
This synthetic strategy was also easily adapted to investigate the effect of inserting an extra 
methylene unit between the α-carbon (to the hydroxamic acid moiety) and phenyl ring.  This 
homologous scaffold was anticipated to improve compound stability, by reducing the acidity of the α-
proton, whilst enabling us to probe space in the S1 pockets of PfA-M1 and PfA-M17.  Using 4d as the 
starting material, the established procedures for esterification, attachment of the N-Boc/pivaloyl group, 
Suzuki coupling and aminolysis were applied.  In this study, the 4-fluoro (9c, 10c), 4-bromo (9d, 10d), 
4-iodo (9e, 10e), 4-phenyl (9t, 10u) and 1-methylpyrazol-4-yl (9u, 10v) derivatives were synthesized 
for direct comparison to their more truncated counterpart. Representative NMR spectra for the 
synthesized compounds are shown in Supp. Fig. 2–6. 
2.2 PfA-M1 and PfA-M17 inhibitor-bound crystal structures guide compound development 
Here, we determined nine PfA-M1 co-crystal structures (with compounds 9b, 9f, 9m, 9q, 9r, 10b, 
10o, 10q, 10s; Supp. Table 1 and 2, Supp. Fig. 1C), and six PfA-M17 co-crystal structures (with 
compounds 9b, 10b, 10o, 10q, 10r, 10s) (Supp. Table 3, Supp. Fig. 1D).  In all structures clear electron 
density for the bound compounds was observed in the active sites (Supp. Fig. 7).  For PfA-M17, which 
has two copies of the hexamer in the asymmetric unit, the compound binding modes are largely 
conserved in all twelve active sites.  Therefore, when describing PfA-M17 structures, we are referring 
to Chain I, which has the clearest electron density. 
We first investigated the effect of replacing the pyrazole ring of 2 and 3 with either a fluoro- or 
bromo-substituent (9a, 9b and 10a, 10b).  Irrespective of the S1’ anchor used, the bromo-substituted 
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compounds 9b and 10b demonstrated the highest PfA-M1 and PfA-M17 inhibitory activity (for PfA-
M1, the Ki of 9b = 27 nM and 10b = 65 nM; for PfA-M17 the Ki of 9b = 80 nM and 10b = 41 nM, 
Table 1).  Placement of a phenyl ring in the same position resulted in 9f and 10f.  While both 9f and 10f 
demonstrated good PfA-M17 inhibitory activity (Ki values of 55 nM and 7 nM respectively), only 
moderate PfA-M1 inhibition was observed (Ki values of 37 µM and 1.6 µM respectively, Table 1).  
To inform elaboration of the series, we determined the crystal structures of both PfA-M1 and PfA-
M17 with 9b (9b:PfA-M1 at 2.0Å and 9b:PfA-M17 at 2.7Å) and 10b (10b:PfA-M1 at 2.0Å and 
10b:PfA-M17 at 2.6Å).  Although a racemic mixture of both compounds was used for the 
crystallization experiments, the crystal structures showed that both PfA-M1 and PfA-M17 demonstrate 
enantiomeric selectivity.  Electron density in the active site of PfA-M1 demonstrated that only S-9b is 
bound in the crystal, whereas R-10b is preferentially bound (Fig. 2A).  In contrast, only the R-
enantiomer of both 9b and 10b could be fit to electron density in the PfA-M17 binding pocket (Fig. 
2B).  It should be noted however, that the observed electron density is an average of many molecules, 
and it is therefore possible that small fractions of the different enantiomers are bound, but unobserved, 
within the crystal.  Compounds 9b and 10b bear different linkers to the tert-butyl moieties, a carbamate 
on 9b and an amide on 10b, that alters the disposition of substituents in the PfA-M1 S1’ cavity.  The 
carbamate of 9b forms three hydrogen bonds to the main chain of Gly460 and Ala461, which places the 
tert-butyl group in a position to form hydrophobic interactions with Val493 at the end of the pocket.  
Selection of the R-enantiomer of 10b allows the equivalent tert-butyl group to occupy a similar 
position in the PfA-M1 pocket despite the shorter linker (Fig. 2A).  A comparison of these PfA-M1 
structures to the 9b:PfA-M17 and 10b:PfA-M17 structures suggest that the different enantiomeric 
selectivity of the enzymes is due to spatial differences in the S1’ cavities.  PfA-M1 has an enclosed S1’ 
pocket, while the S1’ cavity of PfA-M17 is exposed to solvent and is both larger and shallower than the 
PfA-M1 pocket.  While the interaction between the tert-butyl substituents and Val493 in the PfA-M1 
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cavity is vital, the tert-butyl groups of neither 9b nor 10b form direct interactions with PfA-M17.  
Instead the linkers themselves dominate the protein-inhibitor interactions and bind similarly in both 
9b:PfA-M17 and 10b:PfA-M17; the carbamate of 9b forms water mediated hydrogen bonds with the 
main chain of Gly489 and Ala490, while the carbonyl of 10b forms a direct hydrogen bond with the 
main chain amine of Gly489 (Fig. 2B).  Unfortunately, the different enantiomeric preference exhibited 
by PfA-M1 and PfA-M17 make it difficult to directly compare inhibitory activities between the N-Boc 
and N-pivaloyl series.  As a result, we have largely restricted our comparisons to compounds within the 
same series. 
Despite the different poses adopted by 9b and 10b within the S1’ pockets, the position of the 
hydroxamic acid and bromophenyl moieties are conserved (Fig. 2A and 2B).  Compounds 9b and 10b 
form identical zinc binding interactions with PfA-M1, and the bromophenyl positions overlay closely.  
Similarly, in PfA-M17, the hydroxamic acid and bromophenyl moieties of both 9b and 10b make 
identical active site interactions.  The interactions formed by the hydroxamic acid and bromophenyl 
group of 10b with the enzymes are shown in Fig. 2C (PfA-M1) and 2D (PfA-M17).  In both PfA-M1 
and PfA-M17, the hydroxamic acid of 10b forms a dense network of metallo- and hydrogen bonding 
interactions with the zinc ion/s and surrounding residues (Fig. 2C and 2D), and additionally to the 
catalytic carbonate ion in PfA-M17 (Fig. 2D).  The bromophenyl moiety sits within the hydrophobic S1 
pocket of both enzymes.  In 10b:PfA-M1, the bromine atom is ideally placed to interact with the 
aromatic ring of Tyr575, while the phenyl ring is aligned with the side chain of Val459 (Fig. 2C).  
Similarly, in 10b:PfA-M17, the bromophenyl interacts through hydrophobic interactions with Met396, 
Phe398 and Met392 (Fig. 2D).  
While the bromo-substituted compounds 9b and 10b represent some of the most potent dual PfA-
M1 and PfA-M17 inhibitors to date, they provide little opportunity to build further into the S1 pocket.  
In an effort to probe further into the S1 pocket, we incorporated an extra methylene between the phenyl 
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ring and the α-proton (Table 2).  However, regardless of the substituent incorporated (halogen, phenyl 
or 1-methylpyrazol-4-yl), homologues containing an extra methylene linker generally demonstrated 
poor inhibition.  Compounds bearing the N-Boc moiety were poor inhibitors of both PfA-M1 (Ki values 
of 4.3 – >500 µM, Table 2) and PfA-M17 (Ki values of 2.8 – 21 µM, Table 2), while the N-acyl series 
were reasonable PfA-M17 inhibitors (Ki values of 16 – 740 nM, Table 2) but poor PfA-M1 inhibitors 
(Ki values of 15 – 87 µM, Table 2).  As a result, the compounds of this type were not pursued further. 
Since the incorporation of an extra methylene linker did not improve potency, we sought to 
determine whether the bromo-substituent could be replaced with a phenyl ring that, through further 
elaboration, would allow deeper access within the S1 pocket.  While the biphenyl compounds 9f and 
10f, were excellent inhibitors of PfA-M17 (PfA-M17 Ki of 9f = 55 nM and 10f = 7 nM, Table 1), they 
demonstrated substantially less activity against PfA-M1 than their corresponding bromophenyl 
analogues 9b and 10b (PfA-M1 Ki of 9b = 0.027 µM, while 9f = 37 µM and 10b = 0.065 µM and 10f = 
1.6 µM, Table 1).  To elucidate any structural reason for this loss of activity, we also determined the 
structure of 9f in complex with PfA-M1 (2.1Å).  The 9f:PfA-M1 structure showed that the biphenyl 
dihedral angle is approximately 60° in 9f (Fig. 2E). In an energetically ideal state, biphenyl systems 
rapidly convert between two chiral conformations with dihedral angles of approximately 45°.  
Therefore, restricting the biphenyl system of 9f to a non-ideal 60° dihedral angle likely contributes to 
the reduced inhibitory activity of 9f. Regardless, the observed conformation of the biphenyl places the 
second aromatic ring in a position to interact via edge-face π-stacking with Tyr575, carbonyl-π 
interactions with the main chain oxygen of Glu319, and hydrophobic contacts with Met1034 (Fig. 2E).  
Further, insight into the reduced activity of the biphenyl-substituted 9f and 10f is gained by comparison 
of the S1 pocket structure of 9f:PfA-M1, 9b:PfA-M1, and unliganded PfA-M1. In 9b:PfA-M1 and 
unliganded PfA-M1, Glu572 sits on an active site helix, and the side chain has no set position.  
However, in 9f:PfA-M1, the added phenyl ring of 9f presses against Glu572, which occupies a position 
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away from the S1 pocket (Fig. 2E).  To adopt this position, the main chain of Glu572 has undergone a 
substantial movement, which has shifted a single turn of the active site helix it lies on by > 1Å (Fig. 
2E).  Although aminopeptidases, including PfA-M1, are known to be capable of substantial active site 
flexibility [9, 22], such main chain movements are likely to come at an energetic cost, which may 
account for the loss in PfA-M1 inhibitory activity of 9f compared to 9b.  Despite the kinetic liability of 
the biphenyl group to both the 9f and 10f, its incorporation allows us access to the hydrophilic end of 
the pocket, which is occupied by ordered water molecules in 9f:PfA-M1 (Fig. 2E), and which has not 
previously been accessible to the hydroxamic acid-based compound series.  
2.2 Different S1’ anchors result in different SAR 
Substituting the α-carbon with a biphenyl system has allowed us access deeper into the S1 pocket of 
PfA-M1 and PfA-M17.  Therefore, a variety of substituted-phenyl and heteroaromatic rings were used 
to probe the region.  Compounds 2 and 3, which are both substituted with a pyrazole but differ in the 
S1’ anchor (N-Boc vs N-pivaloyl respectively), demonstrated very similar inhibitory activities for each 
of PfA-M1 (Ki of 2 = 0.85 µM, Ki of 3 = 0.72 µM) and PfA-M17 (Ki of 2 = 0.028 µM, Ki of 3 = 0.028 
µM).  Further, the bromo-substituted phenyl compounds (9b and 10b) behaved similarly (for PfA-M1, 
Ki of 9b = 0.027 µM and Ki of 10b = 0.065 µM; for PfA-M17, Ki of 9b = 0.080 µM and Ki of 10b = 
0.041 µM).  Therefore for each of the compound pairs 2/3 and 9b/10b, the N-Boc analogues inhibited 
PfA-M1 and PfA-M17 with similar activities to their corresponding N-pivaloyl compounds.  This trend 
is not conserved for the remainder of the compounds investigated, with a general trend toward greater 
potency (against both enzymes) for the N-pivaloyl compounds (Table 1).  Although the N-Boc series 
9f-s demonstrates reduced inhibitory activities, the series has allowed us to extract some notable SAR. 
In the N-Boc 9f-s series, fluoro- and trifluoromethyl-substituents were tolerated in both the 2- and 3-
positions of the phenyl ring (9g, 9h, 9j and 9k).  When placed at the 4-position (9i, 9l), a substantial 
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loss in binding to PfA-M1 was observed.  In contrast, substitution at all of the positions was well 
tolerated by PfA-M17.  Isosteric replacement of the phenyl ring with pyridyl (9n and 9o) and 
thiophenyl rings (9p) was also investigated.  Both 3- and 4-pyridyl analogues 9n and 9o demonstrated 
reasonable inhibitory activity for PfA-M1, but lost activity against PfA-M17.  The thiophenyl analogue 
9p and the phenyl analogue 9f have similar inhibition activities.  The more polar substituted 
compounds 9q-9s were able to maintain inhibitory activity against both enzymes.  Although the most 
potent of these, 9s, which bears an amidoxime moiety in the 4-position of the phenyl ring, has regained 
the PfA-M17 inhibitory activity of the bromophenyl substituted compound 9b (Ki of 9b for PfA-M17 = 
80 nM; Ki of 9s for PfA-M17 = 18 nM), it still demonstrates substantially reduced PfA-M1 inhibitory 
activity (Ki of 9b for PfA-M1 = 27 nM; Ki of 9s for PfA-M1 = 400 nM).  Generally, replacement of the 
pyrazole ring of compound 2 did not improve binding to PfA-M17, and only the bromo analogue 9b 
demonstrated notable improvement for PfA-M1 binding.  With the aim of finding a binding feature of 
the N-Boc series that we could exploit to improve the activity of the series, we determined the crystal 
structures of PfA-M1 in complex with 9m, 9q and 9r (Supp. Table 1 & Supp. Fig 1C).  However, the 
structures gave us no added insight into the reason for the reduced activity of this series, and the series 
was therefore discontinued. 
2.3 Phenyl substituted N-pivaloyl series probes new region of PfA-M1 and PfA-M17 S1 pocket 
Similarly to the N-Boc series 9f-s, a variety of substituted-phenyl and heteroaromatic rings were 
used to probe the S1 pocket of PfA-M1 and PfA-M17 with the N-pivaloyl series 10f-t.  Fluoro-
substitution of the phenyl ring at the 2-, 3- or 4-positions (10g, 10h and 10i, respectively) alone had 
little effect on inhibition of either PfA-M1 or PfA-M17.  This trend is translated to the di-fluorinated 
compounds (10j-10m) that exhibited only minor differences in PfA-M1 and PfA-M17 inhibitory 
activity.  However, while the 2,4,6-trifluorophenyl substituted 10n was a moderate PfA-M1 inhibitor 
(Ki = 5.9 µM) and an excellent PfA-M17 inhibitor (Ki = 2.5 nM), the 3,4,5-trifluorophenyl substituted 
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10o is a potent, nanomolar inhibitor of both PfA-M1 (Ki = 78 nM) and PfA-M17 (Ki = 60 nM).  
Finally, compounds 10r-10t, which are substituted with more polar groups, potently inhibited PfA-
M17, but were less active against PfA-M1.  Overall, compound 10o represents the most exciting lead, 
having regained the potent, dual inhibition activity of the bromo-substituted compound 10b.  Therefore, 
we determined the crystal structures of 10o in complex with PfA-M1 (1.9Å) and PfA-M17 (2.1Å).  
Since 10q also demonstrates reasonable dual inhibition, and represents a substantially different 
chemotype to 10o, we also determined the crystal structures of 10q:PfA-M1 (1.95Å) and 10q:PfA-M17 
(2.2Å). 
When bound to PfA-M1, the position of the biaryl of 10o compares with that of 9f, despite the 
different S1’ anchors.  The moiety therefore makes the same interactions with Tyr575 (edge-face π-
stacking), Met1034 (hydrophobic) and Glu319 (carbonyl-π) (Fig. 3A).  The fluoro-substituents sit 
deeper into the S1 pocket than any other hydroxamic-acid based inhibitor.  In fact, the only other PfA-
M1 inhibitor that has probed this region is the organophosphorus aminopeptidase inhibitor, Co4 [9, 10, 
23].  Although the fluoro groups of 10o did not displace any of the ordered water molecules as 
anticipated from the 9f:PfA-M1 structure, they have entered into an intricate network of water-
mediated hydrogen-bonds, in which the fluorine atoms act as acceptors.  These additional interactions 
are likely to account for the improved PfA-M1 inhibitory activity of 10o over 10f.  
The structure of 10q:PfA-M1 showed that 10q adopts a different binding pose compared to other 
inhibitors of the series, aligned to the opposite face of the S1 pocket (Fig. 3B).  Whereas the biaryl 
dihedral angle of 9p and 10f is approximately 60°, the thiophene ring of 10q sits co-planar to adjacent 
phenyl ring (Fig. 3C).  This allows the thiophene ring to maintain the π-stacking interactions with 
Tyr575, albeit in a face-face configuration, rather than edge-face.  Interactions are also observed 
between the thiophene ring and Met1034 and the main chain carbonyl of Glu572 (Fig. 3C). 
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The presence of two different PfA-M1 binding poses for 10f/10o and 10q demonstrate that there 
remains additional room for elaboration in the S1 pocket.  Compounds 10s and 10t possess larger 
amidoxime moieties at the 3- and 4-positions of the phenyl ring, and while neither compound displayed 
potent PfA-M1 inhibition, the crystal structure of 10s:PfA-M1 was determined to establish how the 
protein accommodates the larger amidoxime group.  While the data showed clear electron density in 
the binding pocket, modelling of the compound in a single conformation could not satisfy the density.  
Therefore, the compound was modelled in two different conformations (Fig. 3d), that are comparable 
to the two different conformations adopted by 10f/10o and 10q.  Conformation A of 10s resembles the 
pose adopted by 10q, with the phenyl ring undergoing face-face π-stacking with Tyr575.  In this 
position, the added amidoxime substituent pushes against Glu572, pushing it further out of the pocket, 
and causing disorder of the loop 570-574 (shown in red in Fig. 3D).  The amidoxime itself makes 
hydrogen bonds with the main chain oxygen of Glu572, and a water-mediated hydrogen bond with the 
Tyr575 carbonyl oxygen (Fig. 3D).  In conformation B, the distal ring of 10s has rotated approximately 
90°, which changes the geometry of the π-interaction with Tyr575 to an edge-face configuration, 
similar to that undergone by 10f and 10o.  Conformation B also places the amidoxime substituent on 
the opposite side of the pocket compared to conformation A, where it now forms hydrogen bonds with 
Gln317 and Asn458 (both direct and water-mediated, Fig. 3D).  Despite the favorable hydrogen 
bonding interactions observed in both conformations, it is clear that the induced conformational 
changes within the binding pocket come at an energetic cost, thereby accounting for the relatively weak 
inhibition of PfA-M1 by 10s (Ki = 5.4 µM). 
The crystal structures of the same three compounds, 10o, 10q, and 10s bound to PfA-M17 were also 
determined (2.1Å, 2.2Å and 2.6Å respectively).  In contrast to the varying poses adopted when bound 
to PfA-M1, all three compounds bind similarly to PfA-M17, in poses comparable to 10b:PfA-M17 
(Fig. 3E).  In all of the PfA-M17 structures, the R-enantiomer is preferentially bound, with the first 
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phenyl ring of 10b, 10o, 10q, and 10s placed in the same position.  This allows the second rings (3,4,5-
trifluorophenyl in 10o, 3-(amidoximo)phenyl in 10s, and thiophene in 10q) to extend deep into the 
pocket.  The different sizes of the substituents is accommodated for in PfA-M17 by adjustments in the 
position of the Met392 side-chain, which flexes in and out of the pocket depending on the potential for 
interactions (with 10b, 10o and 10q) or repulsion (10s) (Fig. 3E).  The phenyl rings themselves sit 
against the hydrophobic side of the S1 pocket lined by Met396, Phe398 and Leu395 but cause no 
perturbation to the position or architecture of the pocket.  In order to determine how the more polar 
compound 10r is capable of potent PfA-M17 inhibition, we also determined the crystal structure of 
10r:PfA-M17 (2.5Å).  The structure showed that 10r binds similarly to 10o, 10q, and 10s, and 
provided no additional information with which to elaborate. 
Compound 10o is one of the most potent, dual inhibitors of PfA-M1 and PfA-M17 described.  Its 
ability to potently inhibit both enzymes is due to the dual nature of the 3,4,5-trifluorophenyl 
substituent.  While the fluorine atoms of 10o interact with PfA-M1 through a dense hydrogen-bonding 
network (Fig. 3A), they interact with PfA-M17 strictly through hydrophobic interactions with Leu492, 
Phe583, and Met392 (Fig. 3F). 
2.4 Dual PfA-M1 and PfA-M17 inhibitors are active against multi-drug resistant Pf 
To determine the effect of our dual PfA-M1/PfA-M17 inhibitors on Pf in culture, we used an image-
based assay to measure the growth inhibition on Pf strain 3D7 for selected compounds in the series 
(Table 3).  Lead compounds 2 and 3 were previously reported to inhibit Pf-3D7 with IC50 values of 783 
nM and 227 nM, respectively [17].  The N-pivaloyl series demonstrates superior activity against Pf-
3D7 growth compared to the N-Boc series, which we predict to be the result of better cellular 
penetration and stability. Within the N-pivaloyl series, we were excited to observe that incorporating a 
biaryl system generally led to improved inhibition of Pf growth compared to the parent compound 3 
(IC50 of 10f = 96 nM).  The exceptions to this trend were compounds 10s and 10t, in which the 
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amidoxime moieties likely interfere with cellular penetration.  All of the fluorophenyl-substituted 
compounds performed well, inhibiting Pf-3D7 growth in the range of 109–162 nM.  The potent dual 
inhibitor, 10o, demonstrated an IC50 of 126 nM.  The best cellular inhibitors of the series included: 10f, 
bearing the unsubstituted biphenyl system (IC50 = 96 nM), the 2,4-difluorophenyl substituted 10j (IC50 
= 109 nM), and 10q, which is substituted with the thiophen-3-yl moiety (IC50 = 103 nM). 
Given the potent inhibition of Pf-3D7 growth, we were also interested to determine how the 
compounds performed in other strains, including drug-resistant strains.  Therefore, we tested the effect 
of compound treatment on malarial strains Dd2 [24, 25] (chloroquine-, quinine-, pyrimethamine- and 
sulfadoxine-resistant) and NITD609-RDd2 clone#2 (abbreviated here on as Dd2 SpiroR), which is 
resistant to the same parent drugs as Dd2, but additionally resistant to spiroindolones, aminopyrazoles, 
dihydroisoquinolones and pyrazolamindes) (Table 3) [26-29].  Again, the compounds demonstrated 
potent inhibition of parasite growth.  The most potent inhibitors of Pf-3D7 growth also demonstrated 
potent activity against Dd2 Parent and Dd2 SpiroR, particularly 10o (IC50 Dd2 Parent = 189 nM, IC50 
Dd2 SpiroR = 107 nM), and 10q (IC50 Dd2 Parent = 110 nM, IC50 Dd2 SpiroR = 100 nM).  Finally, we 
also tested the compounds against human mammalian cell line HEK293, to predict whether we may 
encounter human toxicity with our compound series.  No toxicity to HEK293 cells was observed when 
treated with each of the compounds listed in Table 3 up to a 40 µM concentration over a period of 72 
hours. 
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2.5 Preliminary pharmacokinetic studies 
The physicochemical and metabolic stability characteristics of the potent dual inhibitor 10o are 
presented in Table 4.  Compound 10o demonstrated moderate to good solubility, with no pH 
dependence noted between pH 2 and 6.5.  The estimated partition coefficient was moderate, with 
LogD7.4 value of 3.0.  The stability of 10o in mouse and human plasma was investigated and there was 
no evidence of degradation over the course of a 4-6 h incubation at 37°C.  The metabolic stability of 
10o was assessed by incubating the compound at 1 µM in mouse and human liver microsomes at 37°C 
and 0.4 mg/mL protein concentration.  Compound 10o possessed half-life of 69 minutes in mouse and 
221 minutes in human microsomes, with low-to-intermediate in vitro intrinsic clearance (CLint) values 
calculated in each species, which is an indicator of good metabolic stability. 
 
3. Conclusions 
Antimalarial drug resistance represents a major threat to global health. While progress towards a 
malaria vaccine continues [30, 31], the continued development of antimalarial agents that work via 
novel mechanisms is absolutely required.  We have described the design, synthesis and characterisation 
of novel compounds that inhibit the essential Pf MAPs, PfA-M1 and PfA-M17.  Using a 
comprehensive structure-guided medicinal chemistry approach, we elaborated the hydroxamic acid-
based compounds deep into the S1 pocket of both enzymes, which resulted in a series of potent, dual 
PfA-M1 and PfA-M17 inhibitors.  Furthermore, we determined that the compounds possess nanomolar 
anti-malarial activity against Pf-3D7 parasites, and excitingly, drug resistant strains Dd2 and Dd2 
SpiroR.  One of the most promising analogues, compound 10o, was shown to possess good 
physicochemical properties and excellent plasma stability. The observed half-life and in vitro CLint in 
mouse and human liver microsomes were indicators of good metabolic stability. 
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In summary, this study has identified a series of potent dual acting PfA-M1 and PfA-M17 inhibitors 
that show good anti-malarial activity against Pf-3D7 parasites and have the potential to be developed 
into pre-clinical candidates. 
 
4. Experimental section 
4.1. General remarks 
Chemicals and solvents were purchased from standard suppliers and used without further 
purification.  Davisil® silica gel (40-63µm), for flash column chromatography (FCC) was supplied by 
Grace Davison Discovery Sciences (Victoria, Australia) and deuterated solvents were purchased from 
Cambridge Isotope Laboratories, Inc. (USA, distributed by Novachem PTY. Ltd, Victoria, Australia). 
Unless otherwise stated, reactions were carried out at ambient temperature. Reactions were 
monitored by thin layer chromatography on commercially available pre-coated aluminium-backed 
plates (Merck Kieselgel 60 F254).  Visualization was by examination under UV light (254 and 366 nm).  
General staining carried out with KMnO4 or phosphomolybdic acid.  A solution of Ninhydrin (in 
ethanol) was used to visualize primary and secondary amines.  A solution of FeCl3 (5% in 0.5M 
HCl(aq)) was used to visualize hydroxamic acids.  All organic extracts collected after aqueous work-up 
procedures were dried over anhydrous Na2SO4 before gravity filtering and evaporation to dryness.  
Organic solvents were evaporated in vacuo at ≤ 40°C (water bath temperature).  Purification using 
preparative layer chromatography (PLC) was carried out on Analtech preparative TLC plates (200 mm 
x 200 mm x 2 mm). 
1H NMR, 13C NMR and 19F NMR spectra were recorded on a Bruker Avance Nanobay III 400MHz 
Ultrashield Plus spectrometer at 400.13 MHz, 100.62 MHz, and 376.46 MHz, respectively.  Chemical 
shifts (δ) are recorded in parts per million (ppm) with reference to the chemical shift of the deuterated 
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solvent.  Unless otherwise stated, samples were dissolved in CDCl3.  Coupling constants (J) and 
carbon-fluorine coupling constants (JCF) are recorded in Hz and the significant multiplicities described 
by singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), multiplet (m), doublet of doublets (dd), 
doublet of triplets (dt). Spectra were assigned using appropriate COSY, DEPT, HSQC and HMBC 
sequences. 
LC-MS were run to verify reaction outcome and purity using either system A or B. System A: an 
Agilent 6100 Series Single Quad coupled to an Agilent 1200 Series HPLC.  The following buffers were 
used; buffer A: 0.1% formic acid in H2O; buffer B: 0.1% formic acid in MeCN.  The following 
gradient was used with a Phenomenex Luna 3µM C8(2) 15 x 4.6 mm column, and a flow rate of 0.5 
mL/min and total run time of 12 min; 0–4 min 95% buffer A and 5% buffer B, 4–7 min 0% buffer A 
and 100% buffer B, 7–12 min 95% buffer A and 5% buffer B.  Mass spectra were acquired in positive 
and negative ion mode with a scan range of 0–1000 m/z at 5V. UV detection was carried out at 254 nm.  
System B: an Agilent 6120 Series Single Quad coupled to an Agilent 1260 Series HPLC.  The 
following buffers were used; buffer A: 0.1% formic acid in H2O; buffer B: 0.1% formic acid in MeCN.  
The following gradient was used with a Poroshell 120 EC-C18 50 x 3.0 mm 2.7 micron column, and a 
flow rate of 0.5 mL/min and total run time of 5 min; 0–1 min 95% buffer A and 5% buffer B, from 1-
2.5 min up to 0% buffer A and 100% buffer B, held at this composition until 3.8 min, 3.8–4 min 95% 
buffer A and 5% buffer B, held until 5 min at this composition.  Mass spectra were acquired in positive 
and negative ion mode with a scan range of 100–1000 m/z.  UV detection was carried out at 214 and 
254 nm. All retention times (tR) are quoted in minutes. 
HRMS analyses were carried out on an Agilent 6224 TOF LC/MS Mass Spectrometer coupled to an 
Agilent 1290 Infinity (Agilent, Palo Alto, CA).  All data were acquired and reference mass corrected 
via a dual‐spray electrospray ionisation (ESI) source.  Acquisition was performed using the Agilent 
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Mass Hunter Data Acquisition software version B.05.00 Build 5.0.5042.2 and analysis was performed 
using Mass Hunter Qualitative Analysis version B.05.00 Build 5.0.519.13. 
Analytical HPLC was acquired on an Agilent 1260 Infinity Analytical HPLC fitted with a Zorbax 
Eclipse Plus C18 Rapid Resolution 4.6 × 100 mm 3.5‐Micron column with UV detection at 254 nm.  
The following buffers were used; buffer A: 0.1% TFA in H2O; buffer B: 0.1% TFA in MeCN.  
Samples were run in a gradient of 5 – 100% buffer B in buffer A over 9 min, followed by isocratic 
100% buffer B for 1 min at a flow rate of 1.0 mL/min. 
Preparative HPLC was performed using an Agilent 1260 infinity coupled with a binary preparative 
pump and Agilent 1260 FC-PS fraction collector, using Agilent OpenLAB CDS software (Rev 
C.01.04), and an Altima 5µM C8 22 x 250 mm column.  The following buffers were used; buffer A: 
H2O; buffer B: MeCN, with sample being run at a gradient of 5% buffer B to 100% buffer B over 20 
min, at a flow rate of 20 mL/min.  All screening compounds were of > 95% purity unless specified in 
the individual monologue. 
Instant JChem was used for structure database management and SMILES string generation (Supp. 
Table 4); Instant JChem 6.3.3, 2014, ChemAxon (http://www.chemaxon.com). 
4.2 Chemistry 
4.2.1. General Procedure A: Methyl ester and N-Boc protection of amino acids 
The amino acid (1.0 mmol, 1.0 eq) was dispersed in MeOH (1.0 mL per 0.21 mmol of amino acid) 
with concd H2SO4 (1.8 eq). The mixture was refluxed overnight, at which point LC-MS analysis 
indicated complete conversion had taken place.  The mixture was cooled then concentrated under 
reduced pressure. The resulting residue was basified with sat. NaHCO3 (aq), then extracted with DCM. 
The combined organic layers were concentrated under reduced pressure.  This was taken up into water 
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and THF (5:1), before adding in Boc2O (1.05 eq), and stirring at room temperature overnight.  The 
mixture was diluted with water, before extraction with DCM. Concentration of the combined organic 
layers gave the desired product.  
4.2.2. General Procedure B: Methyl ester and N-pivamide protection of amino acids 
The amino acid (1.0 mmol, 1.0 eq) was dispersed in MeOH (1.0 mL per 0.21 mmol of amino acid) 
with concd H2SO4 (1.8 eq).  The mixture was refluxed overnight, at which point LC-MS analysis 
indicated complete conversion had taken place.  The mixture was cooled then concentrated under 
reduced pressure.  The resulting residue was basified with sat. NaHCO3 (aq), then extracted with DCM.  
The combined organic layers were concentrated under reduced pressure.  The crude compound was 
taken up in DCM and triethylamine (2.2 eq) was added, followed by pivaloyl chloride (1.1 eq).  The 
reaction mixture was stirred at room temperature for 2 h and then diluted with DCM, washed with 
water and further extracted with DCM.  Concentration of the organic layer gave the desired product. 
4.2.3. General Procedure C: Suzuki coupling of arylbromide (5b, 5d, 6b or 6d) with boronic acids or 
boronate esters 
 Aryl bromide (0.20 g) and the appropriate boronic acid or boronate ester (1.5 eq) were dispersed in 
degassed THF (3 mL) and degassed 1M Na2CO3 (aq) (1 mL) in a 10 mL microwave vessel.  A steady 
stream of nitrogen was bubbled through the mixture for 5 min, before adding PdCl2(PPh3)2 (41 mg, 0.1 
eq), then immediately sealing the tube.  The mixture was heated at 100 °C in an aluminium heating 
block for 2 h, at which point LC-MS analysis indicated the reaction was complete.  After cooling, the 
mixture was diluted with EtOAc (10 mL) and water (10 mL), and the aqueous layer discarded.  The 
organic layer was filtered through a plug of cotton wool, before concentration and further purification 
by FCC (eluent DCM or MeOH/DCM 0:100 to 5:95 for more polar compounds). 
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4.2.4. General Procedure D: Direct aminolysis of methyl esters to corresponding hydroxamic acids 
The appropriate methyl ester (0.40–0.55 mmol) was dissolved in anhydrous MeOH (0.5 mL) at 
room temperature in a nitrogen-flushed vessel.  In a separate nitrogen flushed vial, NH2OH.HCl (139 
mg, 2 mmol) and 5M KOH/anhydrous MeOH (0.5 mL, 2.5 mmol) were mixed, then sonicated for 30 
sec.  The resulting suspension was added to the methanolic ester solution with washings of anhydrous 
MeOH (1 mL).  The mixtures were stirred at RT overnight and monitored by LC-MS analysis. The 
mixtures were directly dry-loaded on to Isolute HM-N® (Biotage), before purification by FCC (eluent 
MeOH/DCM 0:100 to 10:90). 
4.2.5. General Procedure E: CDI-mediated coupling of carboxylic acids with hydroxylamine to give 
the corresponding hydroxamic acid 
The appropriate carboxylic acid (1 eq) was dissolved in anhydrous THF (1-5 mL/mmol) at RT under 
an atmosphere of nitrogen, and CDI (1.5 eq) was added.  The mixture was stirred at RT for 1 h, before 
adding in NH2OH.HCl (2 eq). Stirring was continued at RT for 24 to 48 h, before diluting the mixture 
with sat. NH4Cl (aq) (20 mL), then extracting with EtOAc (3 x 20 mL). The combined organic layers 
were washed with sat. NaHCO3 (aq) (20 mL) and brine (20 mL), before concentration under reduced 
pressure. The resulting crude product was further purified by FCC (eluent MeOH/DCM 0:100 to 
10:90). 
4.2.6. Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-fluorophenyl)acetate (5a) 
2-Amino-2-(4-fluorophenyl)acetic acid (4a) (0.28 g, 1.7 mmol) was converted to the title compound 
according to General Procedure A, to give 0.30 g (64%) of clear, colourless oil after purification by 
FCC (eluent EtOAc/PE 0:100 to 40:60). 1H NMR δ 7.37–7.30 (m, 2H), 7.08–7.00 (m, 2H), 5.57 (br. d, 
J = 5.0 Hz, 1H), 5.30 (d, J = 7.0 Hz, 1H), 3.72 (s, 3H), 1.43 (s, 9H); 13C NMR δ 171.6, 162.8 (d, JCF = 
247.2 Hz), 154.9, 133.0, 129.0 (d, JCF = 8.3 Hz), 115.9 (d, JCF = 21.7 Hz), 80.4, 57.0, 52.9, 28.4; m/z 
HRMS (TOF ES+) C14H18FNNaO4 [M+Na]+ calcd 306.1112; found 306.1100; LC-MS tR: 3.74 min. 
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4.2.7. Methyl 2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)acetate (5b) 
2-Amino-2-(4-bromophenyl)acetic acid (4b) (4.87 g, 21.2 mmol) was converted to the title 
compound according to General Procedure A, to give 7.56 g (quantitative yield) of pale brown oil, 
which slowly solidified to an off-white solid. 1H NMR δ 7.48 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 
2H), 5.77–5.34 (m, 1H), 5.35–5.00 (m, 1H), 3.72 (s, 3H), 1.49–1.22 (m, 9H)*; 13C NMR δ 165.9, 
156.6, 135.4, 132.2, 128.9, 122.6, 77.7, 57.2, 53.1, 28.4*, 27.6*; * multiple peaks present due to 
rotameric effects; m/z MS (TOF ES+) C14H18BrNNaO4 [M+Na]+ calcd 366.0; found 366.0; LC-MS tR: 
4.00 min. 
4.2.8. Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-fluorophenyl)propanoate (5c) 
2-Amino-3-(4-fluorophenyl)propanoic acid (4c) (0.28 g, 1.5 mmol) was converted to the title 
compound according to General Procedure A, to give 0.45 g (quantitative yield) of a pale yellow oil, 
which slowly solidified to a pale yellow solid.  1H NMR δ 7.12–7.04 (m, 2H), 7.01–6.93 (m, 2H), 4.98 
(br. d, J = 7.4 Hz, 1H), 4.56 (dd, J = 13.7/6.1 Hz, 1H), 3.71 (s, 3H), 3.10 (dd, J = 13.9/5.7 Hz, 1H), 
3.00 (dd, J = 13.9/6.1 Hz, 1H), 1.41 (s, 9H); 13C NMR δ 172.3, 162.1 (d, JCF = 245.2 Hz), 155.1, 131.9 
(d, JCF = 3.3 Hz), 130.9 (d, JCF = 8.0 Hz), 115.5 (d, JCF = 21.3 Hz), 80.1, 54.6, 52.4, 37.8, 28.4; m/z 
HRMS (TOF ES+) C15H20FNNaO4 [M+Na]+ calcd 320.1269; found 320.1283; LC-MS tR: 3.76 min. 
4.2.9. Methyl 3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (5d) 
2-Amino-3-(4-bromophenyl)propanoic acid (4d) (2.00 g, 8.19 mmol) was converted to the title 
compound according to General Procedure A, to give 2.74 g (93%) of white solid.  1H NMR δ 7.45–
7.38 (m, 2H), 7.00 (app. d, J = 8.3 Hz, 2H), 4.97 (br. d, J = 7.6 Hz, 1H), 4.57 (dd, J = 13.7/6.1 Hz, 1H), 
3.71 (s, 3H), 3.08 (dd, J = 13.1/5.0 Hz, 1H), 2.98 (dd, J = 13.0/5.4 Hz, 1H), 1.42 (s, 9H); 13C NMR δ 
172.2, 155.1, 135.2, 131.7, 131.1, 121.2, 80.2, 54.3, 52.4, 37.9, 28.4; m/z MS (TOF ES+) 
C15H20BrNNaO4 [M+Na]+ calcd 380.1; found 380.1; LC-MS tR: 3.89 min. 
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4.2.10. Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-iodophenyl)propanoate (5e) 
2-Amino-3-(4-iodophenyl)propanoic acid (4e) (1.00 g, 3.44 mmol) was converted to the title 
compound according to General Procedure A, to give 0.615 g (44%) of white solid after purification by 
FCC (eluent DCM).  1H NMR δ 7.64–7.59 (m, 2H), 6.87 (app. d, J = 8.2 Hz, 2H), 4.97 (br. d, J = 7.8 
Hz, 1H), 4.56 (dd, J = 13.3/5.7 Hz, 1H), 3.71 (s, 3H), 3.07 (dd, J = 13.8/5.6 Hz, 1H), 2.97 (dd, J = 
13.7/6.0 Hz, 1H), 1.41 (s, 9H); 13C NMR δ 172.2, 155.1, 137.7, 135.9, 131.5, 92.7, 80.2, 54.3, 52.5, 
38.0, 28.4; m/z MS (TOF ES+) C15H20INNaO4 [M+Na]+ calcd 428.0; found 428.1; LC-MS tR: 3.93 min.  
4.2.11. Methyl 2-(4-fluorophenyl)-2-pivalamidoacetate (6a) 
2-Amino-2-(4-fluorophenyl)acetic acid (4a) (0.28 g, 1.7 mmol) was converted to the title compound 
according to General Procedure B, to give 0.39 g (88%) of white solid after purification by FCC (eluent 
EtOAc/PE 0:100 to 40:60).  1H NMR δ 7.36–7.29 (m, 2H), 7.08–7.00 (m, 2H), 6.65 (br. d, J = 5.8 Hz, 
1H), 5.50 (d, J = 6.7 Hz, 1H), 3.73 (s, 3H), 1.22 (s, 9H); 13C NMR δ 177.9, 171.7, 162.8 (d, JCF = 247.3 
Hz), 132.9 (d, JCF = 3.2 Hz), 129.0 (d, JCF = 8.4 Hz), 116.1 (d, JCF = 21.8 Hz), 55.8, 53.0, 38.8, 27.5; 
m/z MS (TOF ES+) C14H19FNO3 [MH]+ calcd 268.1; found 268.2; LC-MS tR: 3.61 min. 
4.2.12. Methyl 2-(4-bromophenyl)-2-pivalamidoacetate (6b) 
2-Amino-2-(4-bromophenyl)acetic acid (4b) (1.00 g, 4.35 mmol) was converted to the title 
compound according to General Procedure B, to give 1.34 g (94%) of white solid.  1H NMR δ 7.51–
7.45 (m, 2H), 7.25–7.20 (m, 2H), 6.68 (br. d, J = 6.1 Hz, 1H), 5.48 (d, J = 6.6 Hz, 1H), 3.73 (s, 3H), 
1.21 (s, 9H); 13C NMR δ 177.9, 171.4, 136.1, 132.2, 128.9, 122.7, 56.0, 53.1, 38.8, 27.5; m/z MS (TOF 
ES+) C14H19BrNO3 [MH]+ calcd 328.1; found 328.1; LC-MS tR: 3.76 min. 
4.2.13. Methyl 3-(4-fluorophenyl)-2-pivalamidopropanoate (6c) 
2-Amino-3-(4-fluorophenyl)propanoic acid (4c) (0.28 g, 1.5 mmol) was converted to the title 
compound according to General Procedure B, to give 0.12 g (28%) of white solid, after purification by 
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FCC (eluent DCM).  1H NMR δ 7.07–6.92 (m, 4H), 6.06 (br. d, J = 6.7 Hz, 1H), 4.83 (ddd, J = 
7.5/5.8/5.8 Hz, 1H), 3.73 (s, 3H), 3.15 (dd, J = 13.9/5.8 Hz, 1H), 3.05 (dd, J = 13.9/5.6 Hz, 1H), 1.15 
(s, 9H); 13C NMR δ 178.0, 172.3, 162.1 (d, JCF = 245.3 Hz), 131.8 (d, JCF = 3.3 Hz), 130.9 (d, JCF = 7.9 
Hz), 115.5 (d, JCF = 21.3 Hz), 53.0 (d, JCF = 0.9 Hz), 52.5, 38.8, 37.1, 27.5; m/z MS (TOF ES+) 
C15H21FNO3 [MH]+ calcd 282.2; found 282.2; LC-MS tR: 3.64 min. 
4.2.14. Methyl 3-(4-bromophenyl)-2-pivalamidopropanoate (6d) 
2-Amino-3-(4-bromophenyl)propanoic acid (4d) (2.00 g, 8.19 mmol) was converted to the title 
compound according to General Procedure B, to give 2.57 g (92%) of white solid.  1H NMR δ 7.39 
(app. d, J = 8.3 Hz, 2H), 6.94 (app. d, J = 8.3 Hz, 2H), 6.07 (br. d, J = 7.0 Hz, 1H), 4.83 (dd, J = 
13.0/5.8 Hz, 1H), 3.73 (s, 3H), 3.13 (dd, J = 13.9/5.9 Hz, 1H), 3.04 (dd, J = 13.9/5.5 Hz, 1H), 1.15 (s, 
9H); 13C NMR δ 178.0, 172.2, 135.1, 131.7, 131.1, 121.2, 52.8, 52.5, 38.8, 37.3, 27.5; m/z MS (TOF 
ES+) C15H21BrNO3 [MH]+ calcd 342.1; found 342.1; LC-MS tR: 3.78 min. 
4.2.15. Methyl 3-(4-iodophenyl)-2-pivalamidopropanoate (6e) 
2-Amino-3-(4-iodophenyl)propanoic acid (4e) (1.00 g, 3.44 mmol) was converted to the title 
compound according to General Procedure B, to give 0.768 g (57%) of yellow solid after purification 
by FCC (eluent DCM).  1H NMR δ 7.53–7.47 (m, 2H), 6.79–6.72 (m, 2H), 6.12 (d, J = 7.5 Hz, 1H), 
4.73 (ddd, J = 7.5/5.9/5.9 Hz, 1H), 3.63 (s, 3H), 3.04 (dd, J = 13.8/5.7 Hz, 1H), 2.93 (dd, J = 13.8/6.0 
Hz, 1H), 1.06 (s, 9H); 13C NMR δ 177.7, 171.8, 137.3, 135.6, 131.1, 92.4, 52.6, 52.2, 38.4, 37.0, 27.2; 
m/z MS (TOF ES+) C15H21INO3 [MH]+ calcd 390.1; found 390.1; LC-MS tR: 3.80 min. 
4.2.16. Methyl 2-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetate (7a) 
Phenylboronic acid (106 mg) underwent Suzuki coupling according to General Procedure C, with 
variation to the workup procedure as follows: the cooled reaction mixture was diluted with water (20 
mL) and extracted with EtOAc (3 x 20 mL).  The combined organic layers were washed with brine (20 
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mL), before concentration and FCC purification (DCM) to give 162 mg of colourless crystalline solid 
(81%).  1H NMR δ 7.65–7.53 (m, 4H), 7.50–7.40 (m, 4H), 7.36 (ddd, J = 7.3/3.8/1.2 Hz, 1H), 5.66 (d, J 
= 6.7 Hz, 1H), 5.39 (d, J = 7.3 Hz, 1H), 3.75 (s, 3H), 1.58–1.32 (m, 9H); 13C NMR δ 171.7, 155.0, 
141.5, 140.5, 136.0, 128.9, 127.7, 127.7, 127.6, 127.2, 80.3, 57.4, 52.9, 28.4; m/z MS (TOF ES+) 
C20H23NNaO4 [M+Na]+ calcd 364.2; found 364.2; LC-MS tR: 4.09 min. 
4.2.17. Methyl 2-((tert-butoxycarbonyl)amino)-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)acetate (7b) 
2-Fluorophenylboronic acid (122 mg) underwent Suzuki coupling according to General Procedure 
C, to give 163 mg (78%) of white solid.  1H NMR δ 7.54 (dd, J = 8.3/1.6 Hz, 2H), 7.48–7.38 (m, 3H), 
7.32 (dddd, J = 7.0/7.0/5.0/1.8 Hz, 1H), 7.21 (ddd, J = 7.5/7.5/1.2 Hz, 1H), 7.15 (ddd, J = 10.8/8.2/1.1 
Hz, 1H), 5.60 (d, J = 7.1 Hz, 1H), 5.38 (d, J = 7.2 Hz, 1H), 3.75 (s, 3H), 1.51–1.30 (m, 9H); 19F NMR δ 
-117.99; 13C NMR δ 170.5, 159.9 (d, JCF = 247.9 Hz), 154.0, 136.4, 136.1, 130.8 (d, JCF = 3.4 Hz), 
129.7 (d, JCF = 2.0 Hz), 129.4 (d, JCF = 8.1 Hz), 127.4, 124.6 (d, JCF = 3.7 Hz), 116.3 (d, JCF = 22.7 
Hz), 78.3, 57.5, 53.0, 28.5; m/z MS (TOF ES+) C20H22FNNaO4 [M+Na]+ calcd 382.1; found 382.3; LC-
MS tR: 3.99 min.  
4.2.18. Methyl 2-((tert-butoxycarbonyl)amino)-2-(3'-fluoro-[1,1'-biphenyl]-4-yl)acetate (7c) 
3-Fluorophenylboronic acid (122 mg) underwent Suzuki coupling according to General Procedure 
C, to give 175 mg (84%) of white solid.  1H NMR δ 7.61–7.52 (m, 2H), 7.50–7.31 (m, 4H), 7.30–7.20 
(m, 1H), 7.09–7.00 (m, 1H), 5.62 (d, J = 6.6 Hz, 1H), 5.37 (d, J = 7.0 Hz, 1H), 3.75 (s, 3H), 1.52–1.30 
(m, 9H); 19F NMR δ -112.97; 13C NMR δ 174.3, 163.3 (d, JCF = 245.7 Hz), 163.3, 141.4, 140.2, 132.9, 
130.4 (d, JCF = 8.4 Hz), 127.8, 122.9 (d, JCF = 2.8 Hz), 114.5 (d, JCF = 21.4 Hz), 114.1 (d, JCF = 22.0 
Hz), 79.7, 57.4, 53.0, 28.5; m/z MS (TOF ES+) C20H22FNNaO4 [M+Na]+ calcd 382.1; found 382.2; LC-
MS tR: 4.03 min. 
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4.2.19. Methyl 2-((tert-butoxycarbonyl)amino)-2-(4'-fluoro-[1,1'-biphenyl]-4-yl)acetate (7d) 
4-Fluorophenylboronic acid (122 mg) underwent Suzuki coupling according to General Procedure 
C, to give 149 mg (72%) of clear, colourless oil.  1H NMR δ 7.58–7.48 (m, 4H), 7.43 (d, J = 8.2 Hz, 
2H), 7.18–7.06 (m, 2H), 5.64 (d, J = 6.7 Hz, 1H), 5.37 (d, J = 7.2 Hz, 1H), 3.74 (s, 3H), 1.80–1.08 (m, 
9H); 19F NMR δ -115.31; 13C NMR δ 171.7, 162.7 (d, JCF = 246.7 Hz), 155.0, 140.5, 136.7 (d, JCF = 2.7 
Hz), 136.1, 128.8 (d, JCF = 8.1 Hz), 127.7, 127.6, 115.8 (d, JCF = 21.5 Hz), 80.4, 57.4, 52.9, 28.4; m/z 
MS (TOF ES+) C20H22FNNaO4 [M+Na]+ calcd 382.1; found 382.2; LC-MS tR: 4.02 min. 
4.2.20. Methyl 2-((tert-butoxycarbonyl)amino)-2-(2'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)acetate (7e) 
2-(Trifluoromethyl)phenylboronic acid (165 mg) underwent Suzuki coupling according to General 
Procedure C, to give 184 mg (78%) of white solid.  1H NMR δ 7.74 (d, J = 7.8 Hz, 1H), 7.56 (dd, J = 
11.0/4.0 Hz, 1H), 7.46 (dd, J = 7.6/7.6 Hz, 1H), 7.43–7.35 (m, 2H), 7.34–7.27 (m, 3H), 5.76–4.98 (m, 
2H), 3.76 (s, 3H), 1.57–0.89 (m, 9H); 19F NMR δ -56.74; 13C NMR δ 171.8, 155.0, 140.8 (d, JCF = 1.9 
Hz), 140.1, 136.2, 132.1, 131.5 (d, JCF = 0.7 Hz), 129.6, 128.5 (q, JCF = 30.0 Hz), 127.7, 126.7, 126.2 
(q, JCF = 5.3 Hz), 124.2 (q, JCF = 273.6 Hz), 80.4, 57.5, 52.9, 28.4; m/z MS (TOF ES+) C21H22F3NNaO4 
[M+Na]+ calcd 432.1; found 432.2; LC-MS tR: 4.11 min. 
4.2.21. Methyl 2-((tert-butoxycarbonyl)amino)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)acetate (7f) 
3-(Trifluoromethyl)phenylboronic acid (165 mg) underwent Suzuki coupling according to General 
Procedure C, to give 181 mg (76%) of colourless oil.  1H NMR δ 7.80 (s, 1H), 7.73 (d, J = 7.6 Hz, 1H), 
7.65–7.51 (m, 4H), 7.47 (d, J = 8.2 Hz, 2H), 5.91–5.09 (m, 2H), 3.75 (s, 3H), 1.57–1.12 (m, 9H); 19F 
NMR δ -62.63; 13C NMR δ 171.6, 155.0, 141.4, 140.0, 137.0, 131.3 (q, JCF = 32.2 Hz), 130.5 (q, JCF = 
1.0 Hz), 129.4, 127.9, 127.9, 124.3 (q, JCF = 3.6 Hz), 124.2 (q, JCF = 272.4 Hz), 124.0 (q, JCF = 3.8 
Hz), 80.5, 57.4, 53.0, 28.4; m/z MS (TOF ES+) C21H22F3NNaO4 [M+Na]+ calcd 432.1; found 432.2; 
LC-MS tR: 4.15 min. 
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4.2.22. Methyl 2-((tert-butoxycarbonyl)amino)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)acetate (7g) 
4-(Trifluoromethyl)phenylboronic acid (165 mg) underwent Suzuki coupling according to General 
Procedure C, to give 196 mg (83%) of off-white solid.  1H NMR δ 7.69 (d, J = 8.6 Hz, 2H), 7.66 (d, J = 
8.7 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 5.88–5.01 (m, 2H), 3.74 (s, 3H), 1.82–
1.10 (m, 9H); 19F NMR δ -62.43; 13C NMR δ 171.5, 154.9, 144.1, 140.0, 137.2, 129.6 (q, JCF = 32.4 
Hz), 127.9, 127.9, 127.5, 125.9 (q, JCF = 3.7 Hz), 124.3 (q, JCF = 272.0 Hz), 80.4, 57.4, 52.9, 28.4; m/z 
MS (TOF ES+) C21H22F3NNaO4 [M+Na]+ calcd 432.1; found 432.2; LC-MS tR: 4.15 min. 
4.2.23. Methyl 2-((tert-butoxycarbonyl)amino)-2-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yl)acetate (7h) 
3,4,5-Trifluorophenylboronic acid (153 mg) underwent Suzuki coupling according to General 
Procedure C, to give 158 mg (69%) of white solid.  1H NMR δ 7.48 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.6 
Hz, 2H), 7.16 (dd, J = 8.1/6.8 Hz, 2H), 5.69 (d, J = 4.2 Hz, 1H), 5.37 (d, J = 7.0 Hz, 1H), 3.74 (s, 3H), 
1.64–1.11 (m, 9H); 19F NMR δ -133.95 (d, J = 20.5 Hz), -162.26 (dd, J = 20.4/20.4 Hz); 13C NMR δ 
171.4, 154.9, 151.5 (ddd, JCF = 249.8/10.0, 4.2 Hz), 139.5 (ddd, JCF = 251.4/16.1/16.1 Hz), 137.5, 
136.7, 127.9, 127.5, 111.2 (dd, JCF = 15.9/6.0 Hz), 80.5, 57.3, 53.0, 28.4; m/z MS (TOF ES+) 
C20H20F3NNaO4 [M+Na]+ calcd 418.1; found 418.2; LC-MS tR: 4.11 min. 
4.2.24. Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-(pyridin-3-yl)phenyl)acetate (7i) 
Pyridin-3-ylboronic acid (107 mg) underwent Suzuki coupling according to General Procedure C, to 
give 120 mg (60%) of yellow solid.  1H NMR δ 8.82 (s, 1H), 8.60 (d, J = 4.5 Hz, 1H), 8.02–7.82 (m, 
1H), 7.56 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 7.45–7.35 (m, 1H), 5.93–5.03 (m, 2H), 3.74 (s, 
3H), 1.75–0.96 (m, 9H); 13C NMR δ 171.4, 154.9, 147.8, 147.4, 137.6, 137.4, 136.5, 135.3, 128.1, 
127.8, 124.0, 80.4, 57.4, 53.0, 28.4; m/z MS (TOF ES+) C19H23N2O4 [MH]+ calcd 343.2; found 343.2; 
LC-MS tR: 3.40 min. 
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4.2.25. Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-(pyridin-4-yl)phenyl)acetate (7j). 
Pyridin-4-ylboronic acid (107 mg) underwent Suzuki coupling according to General Procedure C, to 
give 170 mg (85%) of dark brown oil.  1H NMR δ 8.66 (s, 2H), 7.89–7.30 (m, 6H), 5.75 (d, J = 4.8 Hz, 
1H), 5.39 (d, J = 6.4 Hz, 1H), 3.73 (s, 3H), 1.43 (s, 9H); 13C NMR δ 171.3, 154.9, 149.7, 148.5, 138.5, 
138.0, 128.0, 127.7, 121.9, 80.5, 57.4, 53.0, 28.4; m/z MS (TOF ES+) C19H23N2O4 [MH]+ calcd 343.2; 
found 343.2; LC-MS tR: 3.28 min. 
4.2.26. Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-(thiophen-3-yl)phenyl)acetate (7k) 
Thiophen-3-ylboronic acid (111 mg) underwent Suzuki coupling according to General Procedure C, 
to give 135 mg (67%) of yellow solid.  1H NMR δ 7.64–7.53 (m, 2H), 7.44 (s, 1H), 7.42–7.31 (m, 4H), 
5.61 (d, J = 6.6 Hz, 1H), 5.34 (d, J = 7.2 Hz, 1H), 3.73 (s, 3H), 1.61–1.18 (m, 9H); 13C NMR δ 171.7, 
154.9, 141.7, 136.2, 135.8, 127.7, 127.1, 126.5, 126.4, 120.8, 80.3, 57.4, 52.9, 28.4; m/z MS (TOF ES+) 
C18H21NNaO4S [M+Na]+ calcd 370.1; found 370.2; LC-MS tR: 3.94 min.  
4.2.27. Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)acetate (7l) 
1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (181 mg) underwent Suzuki 
coupling according to General Procedure C, to give 127 mg (64%) of off-white solid.  1H NMR δ 7.74 
(s, 1H), 7.60 (s, 1H), 7.43 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 5.83–5.49 (m, 1H), 5.47–5.22 
(m, 1H), 3.94 (s, 3H), 3.71 (s, 3H), 1.61–1.16 (m, 9H); 13C NMR δ 171.7, 154.9, 136.5, 135.1, 132.7, 
127.8, 127.4, 126.1, 122.7, 80.3, 57.4, 52.8, 39.2, 28.4; m/z MS (TOF ES+) C18H24N3O4 [MH]+ calcd 
346.2; found 346.2; LC-MS tR: 3.62 min. 
4.2.28. Methyl 2-((tert-butoxycarbonyl)amino)-2-(3'-cyano-[1,1'-biphenyl]-4-yl)acetate (7m) 
3-Cyanophenylboronic acid (128 mg) underwent Suzuki coupling according to General Procedure 
C, to give 137 mg (64%) of clear, colourless oil.  1H NMR δ 7.82 (s, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.62 
(ddd, J = 7.7/1.3/1.3 Hz, 1H), 7.57–7.50 (m, 3H), 7.47 (d, J = 8.3 Hz, 2H), 5.71 (d, J = 6.8 Hz, 1H), 
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5.38 (d, J = 7.1 Hz, 1H), 3.73 (s, 3H), 1.70–0.94 (m, 9H); 13C NMR δ 171.4, 154.9, 141.8, 139.0, 
137.4, 131.5, 131.0, 130.7, 129.8, 128.0, 127.7, 118.8, 113.1, 80.4, 57.3, 53.0, 28.4; m/z MS (TOF ES+) 
C21H22N2NaO4 [M+Na]+ calcd 389.1 found 389.2; LC-MS tR: 3.87 min. 
4.2.29. Methyl 2-((tert-butoxycarbonyl)amino)-2-(4'-cyano-[1,1'-biphenyl]-4-yl)acetate (7n) 
4-Cyanophenylboronic acid (128 mg) underwent Suzuki coupling according to General Procedure C, to 
give 158 mg (74%) of white solid.  1H NMR δ 7.71 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.3 Hz, 2H), 7.57 
(d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 5.70 (d, J = 6.7 Hz, 1H), 5.38 (d, J = 7.1 Hz, 1H), 3.73 (s, 
3H), 1.57–1.20 (m, 9H); 13C NMR δ 171.4, 154.8, 145.0, 139.3, 137.7, 132.7, 127.9, 127.82, 127.77, 
118.9, 111.2, 80.4, 57.3, 53.0, 28.4; m/z MS (TOF ES+) C21H23N2O4 [MH]+ calcd 367.2; found 367.2; 
LC-MS tR: 3.85 min. 
4.2.30. Methyl 3-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)propanoate (7o) 
Phenylboronic acid (102 mg) underwent Suzuki coupling according to General Procedure C, to give 
135 mg (68%) of white solid.  1H NMR δ 7.60–7.50 (m, 4H), 7.47–7.40 (m, 2H), 7.37–7.31 (m, 1H), 
7.23–7.17 (m, 2H), 5.02 (br. d, J = 8.0 Hz, 1H), 4.63 (dd, J = 13.9/6.1 Hz, 1H), 3.74 (s, 3H), 3.17 (dd, J 
= 13.8/5.7 Hz, 1H), 3.09 (dd, J = 13.8/6.1 Hz, 1H), 1.43 (s, 9H); 13C NMR δ 172.5, 155.3, 140.9, 140.1, 
135.2, 129.9, 128.9, 127.4 (3 × CH), 127.2, 80.1, 54.5, 52.4, 38.1, 28.4; m/z MS (TOF ES+) 
C21H26NNaO4 [M+Na]+ calcd 378.2; found 378.2; LC-MS tR: 4.04 min. 
4.2.31. Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)propanoate (7p) 
1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (174 mg) underwent Suzuki 
coupling according to General Procedure C, to give 148 mg (74%) of white solid.  1H NMR δ 7.73 (d, J 
= 0.7 Hz, 1H), 7.58 (s, 1H), 7.41–7.36 (m, 2H), 7.11 (app. d, J = 8.1 Hz, 2H), 5.00 (br. d, J = 8.0 Hz, 
1H), 4.58 (dd, J = 13.8/6.0 Hz, 1H), 3.93 (s, 3H), 3.72 (s, 3H), 3.11 (dd, J = 13.8/5.7 Hz, 1H), 3.04 (dd, 
J = 13.8/6.1 Hz, 1H), 1.41 (s, 9H); 13C NMR δ 172.5, 155.2, 136.8, 134.1, 131.5, 129.9, 126.9, 125.7, 
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123.0, 80.1, 54.5, 52.4, 39.2, 38.1, 28.4; m/z MS (TOF ES+) C19H26N3O4 [MH]+ calcd 360.2; found 
360.2; LC-MS tR: 3.57 min.  
4.2.32. Methyl 2-([1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8a) 
Phenylboronic acid (112 mg) underwent Suzuki coupling according to General Procedure C, to give 
144 mg (73%) of white solid.  1H NMR δ 7.60–7.54 (m, 4H), 7.47–7.40 (m, 4H), 7.38–7.32 (m, 1H), 
6.68 (br. d, J = 6.5 Hz, 1H), 5.58 (d, J = 6.8 Hz, 1H), 3.76 (s, 3H), 1.24 (s, 9H); 13C NMR δ 178.1, 
171.8, 141.6, 140.6, 135.8, 129.0, 127.9, 127.69, 127.66, 127.3, 56.3, 53.0, 38.8, 27.6; m/z MS (TOF 
ES+) C20H24NO3 [MH]+ calcd 326.2; found 326.2; LC-MS tR: 3.84 min. 
4.2.33. Methyl 2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8b) 
2-Fluorophenylboronic acid (90 mg) underwent Suzuki coupling according to General Procedure C, 
to give 117 mg (80%) of beige solid.  1H NMR δ 7.57–7.51 (m, 2H), 7.46–7.41 (m, 2H), 7.39 (dd, J = 
7.7/1.8 Hz, 1H), 7.30 (dddd, J = 8.1/6.9/5.0/1.8 Hz, 1H), 7.19 (ddd, J = 7.5/7.5/1.2 Hz, 1H), 7.13 (ddd, 
J = 10.8/8.2/1.1 Hz, 1H), 6.73 (d, J = 6.7 Hz, 1H), 5.59 (d, J = 6.8 Hz, 1H), 3.74 (s, 3H), 1.25 (s, 9H); 
19F NMR δ -119.0; 13C NMR δ 178.0, 171.6, 159.7 (d, JCF = 248.0 Hz), 136.1 (2C), 130.7 (d, JCF = 3.4 
Hz), 129.6 (d, JCF = 3.0 Hz), 129.3 (d, JCF = 8.3 Hz), 128.3 (d, JCF = 13.3 Hz), 127.3, 124.5 (d, JCF = 
3.7 Hz), 116.2 (d, JCF = 22.7 Hz), 56.2, 52.9, 38.7, 27.4; m/z MS (TOF ES+) C20H23FNO3 [MH]+ calcd 
344.4; found 344.2; LC-MS tR: 3.83 min. 
4.2.34. Methyl 2-(3'-fluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8c) 
3-Fluorophenylboronic acid (90 mg) underwent Suzuki coupling according to General Procedure C, 
to give 78 mg (53%) of white solid.  1H NMR δ 7.58–7.53 (m, 2H), 7.46–7.30 (m, 4H), 7.28–7.22 (m, 
1H), 7.07–7.00 (m, 1H), 6.76 (d, J = 6.5 Hz, 1H), 5.58 (d, J = 6.7 Hz, 1H), 3.75 (s, 3H), 1.25 (s, 9H); 
19F NMR δ -112.9; 13C NMR δ 178.0, 171.6, 163.2 (d, JCF = 245.7 Hz), 142.8 (d, JCF = 7.7 Hz), 140.2 
(d, JCF = 2.2 Hz), 136.4, 130.4 (d, JCF = 8.4 Hz), 127.8, 127.7, 122.8 (d, JCF = 2.8 Hz), 114.4 (d, JCF = 
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21.2 Hz), 114.0 (d, JCF = 22.0 Hz), 56.2, 53.0, 38.8, 27.5; m/z MS (TOF ES+) C20H23FNO3 [MH]+ calcd 
344.4; found 344.2. 
4.2.35. Methyl 2-(4'-fluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8d) 
4-Fluorophenylboronic acid (128 mg) underwent Suzuki coupling according to General Procedure 
C, to give 159 mg (76%) of yellow solid.  1H NMR δ 7.55–7.48 (m, 4H), 7.44–7.39 (m, 2H), 7.16–7.08 
(m, 2H), 6.69 (br. d, J = 6.5 Hz, 1H), 5.57 (d, J = 6.7 Hz, 1H), 3.76 (s, 3H), 1.24 (s, 9H); 19F NMR δ -
115.30; 13C NMR δ 178.1, 171.7, 162.7 (d, JCF = 246.8 Hz), 140.6, 136.7 (d, JCF = 3.2 Hz), 135.9, 
128.8 (d, JCF = 8.1 Hz), 127.7 (4 × CH), 115.9 (d, JCF = 21.5 Hz), 56.3, 53.0, 38.8, 27.6; m/z MS (TOF 
ES+) C20H23FNO3 [MH]+ calcd 344.2; found 344.2; LC-MS tR: 3.87 min. 
4.2.36. Methyl 2-(2',4'-difluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8e) 
2,4-Difluorophenylboronic acid (101 mg) underwent Suzuki coupling according to General 
Procedure C, to give 90 mg (58%) of beige solid.  1H NMR δ 7.51–7.32 (m, 5H), 6.97–6.85 (m, 2H), 
6.72 (d, J = 6.6 Hz, 1H), 5.57 (d, J = 6.8 Hz, 1H), 3.75 (s, 3H), 1.23 (s, 9H); 19F NMR δ -111.0 (d, J = 
7.6 Hz), -113.5 (d, J = 7.6 Hz); 13C NMR δ 178.0, 171.6, 162.5 (dd, JCF = 249.4/11.9 Hz), 159.8 (dd, 
JCF = 250.7/11.9 Hz), 136.3, 135.3, 131.5 (dd, JCF = 9.5/4.9 Hz), 129.6 (d, JCF = 2.8 Hz), 127.4, 124.7 
(dd, JCF = 13.6/3.9 Hz), 111.8 (dd, JCF = 21.1/3.8 Hz), 104.5 (dd, JCF = 26.6/25.3 Hz), 56.3, 53.0, 38.8, 
27.5; m/z MS (TOF ES+) C20H22F2NO3 [MH]+ calcd 362.4; found 362.2; LC-MS tR: 3.85 min. 
4.2.37. Methyl 2-(2',6'-difluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8f) 
2,6-Difluorophenylboronic acid (101 mg) underwent Suzuki coupling according to General 
Procedure C, to give 64 mg (42%) of white solid.  1H NMR δ 7.50–7.41 (m, 4H), 7.32–7.19 (m, 1H), 
7.00–6.93 (m, 2H), 6.67 (d, J = 6.8 Hz, 1H), 5.59 (d, J = 6.9 Hz, 1H), 3.74 (s, 3H), 1.24 (s, 9H); 19F 
NMR δ -114.5; 13C NMR δ 178.0, 171.5, 160.1 (dd, JCF = 248.9/7.0 Hz), 136.6, 131.0 (dd, JCF = 
1.9/1.9 Hz), 129.5, 129.2 (dd, JCF = 10.4/10.4 Hz), 127.2, 117.8 (dd, JCF = 18.5/18.5 Hz), 112.0–111.6 
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(m), 56.3, 52.9, 38.8, 27.5; m/z MS (TOF ES+) C20H22F2NO3 [MH]+ calcd 362.4; found 362.2; LC-MS 
tR: 3.82 min. 
4.2.38. Methyl 2-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8g) 
3,4-Difluorophenylboronic acid (101 mg) underwent Suzuki coupling according to General 
Procedure C, to give 154 mg (quantitative yield) of colourless oil.  1H NMR δ 7.52–7.46 (m, 2H), 7.45–
7.39 (m, 2H), 7.33 (ddd, J = 11.5/7.5/2.1 Hz, 1H), 7.28–7.14 (m, 2H), 6.78 (d, J = 6.6 Hz, 1H), 5.56 (d, 
J = 6.6 Hz, 1H), 3.74 (s, 3H), 1.24 (s, 9H); 19F NMR δ -137.4 (d, J = 21.3 Hz), -139.8 (d, J = 21.3 Hz); 
13C NMR δ 178.1, 171.5, 150.5 (dd, JCF = 248.1/12.8 Hz), 150.1 (dd, JCF = 248.8/12.7 Hz), 139.4, 
137.6 (dd, JCF = 5.9/3.9 Hz), 136.4, 127.8, 127.6, 123.1 (dd, JCF = 6.2/3.5 Hz), 117.7 (d, JCF = 17.4 
Hz), 116.0 (d, JCF = 17.8 Hz), 56.2, 53.0, 38.7, 27.4; m/z MS (TOF ES+) C20H22F2NO3 [MH]+ calcd 
362.4; found 362.2; LC-MS tR: 3.86 min. 
3.2.39. Methyl 2-(3',5'-difluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8h) 
3,5-Difluorophenylboronic acid (101 mg) underwent Suzuki coupling according to General 
Procedure C, to give 84 mg (54%) of yellow oil.  1H NMR δ 7.55–7.49 (m, 2H), 7.47–7.40 (m, 2H), 
7.11–7.02 (m, 2H), 6.78 (dddd, J = 8.8/8.8/2.3/2.3 Hz, 2H), 5.57 (d, J = 6.6 Hz, 1H), 3.76 (s, 3H), 1.24 
(s, 9H); 19F NMR δ -109.5; 13C NMR δ 178.2, 171.5, 163.4 (dd, JCF = 248.2/13.1 Hz), 143.9 (dd, JCF = 
9.5/9.5 Hz), 139.2 (dd, JCF = 2.5/2.5 Hz), 137.1, 127.9, 127.7, 112.1–108.1 (m), 102.9 (t, JCF = 
25.4/25.4 Hz), 56.3, 53.1, 38.8, 27.5; m/z MS (TOF ES+) C20H22F2NO3 [MH]+ calcd 362.4; found 
362.2; LC-MS tR: 3.86 min. 
3.2.40. Methyl 2-pivalamido-2-(2',4',6'-trifluoro-[1,1'-biphenyl]-4-yl)acetate (8i) 
2,4,6-trifluorophenylboronic acid (113 mg) underwent Suzuki coupling according to General 
Procedure C, to give 88 mg (54%) of colourless foam.  1H NMR δ 7.43–7.31 (m, 4H), 6.95–6.84 (m, 
2H), 5.51 (d, J = 6.9 Hz, 1H), 3.67 (s, 3H), 1.16 (s, 9H); 19F NMR δ -108.5 (dd, J = 6.1/6.1 Hz), -111.2 
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(d, J = 6.1 Hz); 13C NMR δ 178.0, 171.6, 160.2 (d, JCF = 248.9 Hz), 160.1 (d, JCF = 248.9 Hz), 136.6, 
131.0 (dd, JCF = 1.9/1.9 Hz), 129.5, 127.2, 117.8, (dd, JCF = 18.4/18.4 Hz), 111.9–111.6 (m), 56.3, 
53.0, 38.8, 27.5; m/z MS (TOF ES+) C20H21F3NO3 [MH]+ calcd 380.4; found 380.2; LC-MS tR: 3.84 
min. 
4.2.41. Methyl 2-pivalamido-2-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yl)acetate (8j) 
3,4,5-Trifluorophenylboronic acid (161 mg) underwent Suzuki coupling according to General 
Procedure C, to give 174 mg (75%) of white solid.  1H NMR δ 7.51–7.40 (m, 2H), 7.21–7.10 (m, 2H), 
6.78 (br. d, J = 6.4 Hz, 1H), 5.56 (d, J = 6.6 Hz, 1H), 3.76 (s, 3H), 1.24 (s, 9H); 19F NMR δ -133.9 (d, J 
= 20.5 Hz), -162.2 (dd, J = 20.5/20.5 Hz); 13C NMR δ 178.0, 171.5, 151.6 (ddd, JCF = 249.9/10.1/4.5 
Hz), 140.9–138.1 (m), 138.5–138.4 (m), 137.3, 136.9–136.6 (m), 128.0, 127.6, 111.2 (dd, JCF = 
15.9/6.0 Hz), 56.2, 53.1, 38.8, 27.5; m/z MS (TOF ES+) C20H21F3NO3 [MH]+ calcd 380.2; found 380.2; 
LC-MS tR: 3.94 min. 
4.2.42. Methyl 2-(2',3',4',5',6'-pentafluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8k) 
2,3,4,5,6-Pentafluorophenylboronic acid (136 mg) underwent Suzuki coupling according to General 
Procedure C, to give 99 mg (56%) of colourless oil.  1H NMR δ 7.51–7.38 (m, 4H), 6.73 (d, J = 6.6 Hz, 
1H), 5.61 (d, J = 6.8 Hz, 1H), 3.77 (s, J = 3.2 Hz, 3H), 1.24 (s, 9H); 19F NMR δ -143.08 (dd, J = 
22.8/8.1 Hz), -155.09 (dd, J = 21.0/21.0 Hz), -161.88–-162.07 (m); 13C NMR δ 178.0, 171.4, 145.6–
142.9 (m), 142.1–139.1 (m), 138.2, 139.4–136.5(m), 130.9, 127.6, 126.7, 56.2, 53.1, 38.8, 27.6; m/z 
MS (TOF ES+) C20H19F5NO3 [MH]+ calcd 416.4; found 416.2; LC-MS tR: 3.94 min.  
4.2.43. Methyl 2-pivalamido-2-(4-(thiophen-3-yl)phenyl)acetate (8l) 
Thiophen-3-ylboronic acid (117 mg) underwent Suzuki coupling according to General Procedure C, 
to give 155 mg (77%) of yellow solid.  1H NMR δ 7.61–7.55 (m, 2H), 7.44 (dd, J = 2.9/1.4 Hz, 1H), 
7.40–7.34 (m, 4H), 6.65 (br. d, J = 6.5 Hz, 1H), 5.55 (d, J = 6.8 Hz, 1H), 3.75 (s, 3H), 1.23 (s, 9H); 13C 
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NMR δ 178.0, 171.8, 141.8, 136.3, 135.6, 127.8, 127.2, 126.5, 126.4, 120.8, 56.3, 53.0, 38.8, 27.6; m/z 
MS (TOF ES+) C18H22NO3S [MH]+ calcd 332.1; found 332.2; LC-MS tR: 3.77 min. 
4.2.44. Methyl 2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-2-pivalamidoacetate (8m) 
1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (114 mg) underwent Suzuki 
coupling according to General Procedure C, to give 81 mg (68%) of yellow solid.  1H NMR δ 7.73 (d, J 
= 0.7 Hz, 1H), 7.59 (s, 1H), 7.46–7.42 (m, 2H), 7.36–7.31 (m, 2H), 6.63 (br. d, J = 6.5 Hz, 1H), 5.51 
(d, J = 6.8 Hz, 1H), 3.94 (s, 3H), 3.73 (s, 3H), 1.22 (s, 9H); 13C NMR δ 178.0, 171.8, 136.9, 134.8, 
133.1, 127.8, 127.1, 126.2, 122.7, 56.3, 53.0, 39.3, 38.8, 27.5; m/z MS (TOF ES+) C18H24N3O3 [MH]+ 
calcd 330.2; found 330.2; LC-MS tR: 3.51 min. 
4.2.45. Methyl 2-(3'-cyano-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8n) 
3-Cyanophenylboronic acid (134 mg) underwent Suzuki coupling according to General Procedure 
C, to give 159 mg (74%) of colourless oil.  1H NMR δ 7.84–7.81 (m, 1H), 7.78 (ddd, J = 7.8/1.9/1.3 
Hz, 1H), 7.65–7.62 (m, 1H), 7.58–7.50 (m, 3H), 7.50–7.43 (m, 2H), 6.77 (br. d, J = 6.5 Hz, 1H), 5.58 
(d, J = 6.6 Hz, 1H), 3.76 (s, 3H), 1.24 (s, 9H); 13C NMR δ 178.1, 171.5, 141.9, 139.2, 137.3, 131.6, 
131.1, 130.8, 129.8, 128.0, 127.8, 118.9, 113.2, 56.3, 53.2, 38.8, 27.5; m/z MS (TOF ES+) C20H23FNO3 
[MH]+ calcd 351.2; found 351.2; LC-MS tR: 3.74 min. 
4.2.46. Methyl 2-(4'-cyano-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8o) 
4-Cyanophenylboronic acid (134 mg) underwent Suzuki coupling according to General Procedure 
C, to give 152 mg (71%) of white solid.  1H NMR δ 7.75–7.70 (m, 2H), 7.68–7.63 (m, 2H), 7.59–7.55 
(m, 2H), 7.49–7.45 (m, 2H), 6.76 (br. d, J = 6.5 Hz, 1H), 5.58 (d, J = 6.6 Hz, 1H), 3.76 (s, 3H), 1.24 (s, 
9H); 13C NMR δ 178.0, 171.5, 145.1, 139.4, 137.6, 132.8, 127.97, 127.96, 127.9, 119.0, 111.3, 56.2, 
53.2, 38.8, 27.6; m/z MS (TOF ES+) C20H23FNO3 [MH]+ calcd 351.2; found 351.2; LC-MS tR: 3.74 
min. 
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4.2.47. Methyl 3-([1,1'-biphenyl]-4-yl)-2-pivalamidopropanoate (8p) 
Phenylboronic  acid (107 mg) underwent Suzuki coupling according to General Procedure C, to give 
181 mg (91%) of white solid.  1H NMR δ 7.62–7.49 (m, 4H), 7.48–7.40 (m, 2H), 7.37–7.32 (m, 1H), 
7.19–7.12 (m, 2H), 6.12 (br. d, J = 7.5 Hz, 1H), 4.91 (ddd, J = 7.6/5.7/5.7 Hz, 1H), 3.77 (s, 3H), 3.23 
(dd, J = 13.8/5.8 Hz, 1H), 3.15 (dd, J = 13.8/5.6 Hz, 1H), 1.17 (s, 9H); 13C NMR δ 178.1, 172.4, 140.7, 
140.1, 135.1, 129.9, 128.9, 127.4, 127.3, 127.1, 53.0, 52.5, 38.8, 37.5, 27.5; m/z MS (TOF ES+) 
C21H26NO3 [MH]+ calcd 340.2; found 340.2; LC-MS tR: 3.98 min. 
4.2.48. Methyl 3-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-2-pivalamidopropanoate (8q) 
1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (182 mg) underwent Suzuki 
coupling according to General Procedure C, to give 114 mg (57%) of yellow solid.  1H NMR δ 7.74 (d, 
J = 0.7 Hz, 1H), 7.59 (s, 1H), 7.41–7.36 (m, 2H), 7.09–7.04 (m, 2H), 6.07 (br. d, J = 7.5 Hz, 1H), 4.86 
(dt, J = 7.6, 5.7 Hz, 1H), 3.94 (s, 3H), 3.75 (s, 3H), 3.17 (dd, J = 13.9/5.8 Hz, 1H), 3.09 (dd, J = 
13.8/5.6 Hz, 1H), 1.16 (s, 9H); 13C NMR δ 178.0, 172.4, 136.8, 134.1, 131.6, 130.0, 127.0, 125.7, 
123.0, 53.0, 52.5, 39.3, 38.8, 37.6, 27.5; m/z MS (TOF ES+) C15H21BrNO3 [MH]+ calcd 344.2; found 
344.3; LC-MS tR: 3.47 min. 
4.2.49. tert-Butyl (1-(4-fluorophenyl)-2-(hydroxyamino)-2-oxoethyl)carbamate (9a) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-fluorophenyl)acetate (5a) (200 mg, 0.71 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 140 mg 
(70%) of a white solid.  1H NMR (DMSO-d6) δ 10.88 (s, 1H), 8.97 (s, 1H), 7.49–7.40 (m, 3H), 7.20–
7.12 (m, 2H), 5.05 (d, J = 8.7 Hz, 1H), 1.37 (s, 9H); 13C NMR (DMSO-d6) δ 166.9, 161.6 (d, JCF = 
243.5 Hz), 154.9, 134.9, 129.1 (d, JCF = 8.2 Hz), 115.0 (d, JCF = 21.4 Hz), 78.4, 54.7, 28.2; m/z HRMS 
(TOF ES+) C13H17FN2NaO4 [M+Na]+ calcd 307.1065; found 307.1077; LC-MS tR: 3.37 min; HPLC tR: 
5.28 min, 95%.  
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4.2.50. tert-Butyl (1-(4-bromophenyl)-2-(hydroxyamino)-2-oxoethyl)carbamate (9b) 
2-Amino-2-(4-bromophenyl)acetic acid (4b) (2.00 g, 8.67 mmol) was dissolved in THF (20 mL) and 
water (10 mL) with stirring at RT.  Boc2O (2.09 g, 9.56 mmol, 1 eq) was added, followed by 2M NaOH 
(aq) (5.5 mL, 11 mmol, 1.27 eq).  The mixture was stirred at RT overnight. TLC analysis 
(AcOH/MeOH/DCM 1:10:89) indicated starting material was still present, so Boc2O (0.190 g, 0.1 eq) 
was added and stirring continued for 2 h at RT.  The mixture was concentrated under reduced pressure 
to remove THF, and the resulting aqueous slurry diluted with water (20 mL).  The pH was reduced with 
care to approximately 4, using dilute HCl (aq) (water acidified with 2M HCl (aq) to ~pH 4), before 
extracting with DCM (3 x 20 mL) and concentrating under reduced pressure to give 3.14 g of pale 
yellow viscous oil.  1H NMR indicated impurities were still present, so the crude produce was dispersed 
in 2M NaOH (aq) (30 mL) and washed with Et2O (2 x 30 mL).  The aqueous layer was then carefully 
acidified, as before, then extracted with DCM (3 x 30 mL).  The combined organic extracts were 
concentrated to give 2.361 g (82%) of white foamy solid, which was used without further purification.  
2-(4-Bromophenyl)-2-((tert-butoxycarbonyl)amino)acetic acid (1.00 g, 3.03 mmol) was converted to 
the corresponding hydroxamic acid according to General Procedure E, using CDI (737 mg, 1.5 eq), 
NH2OH.HCl (421 mg, 2 eq) and anhydrous THF (15 mL).  Workup was carried out using 50 mL 
volumes for extraction/washing.  On concentration of the organic layers, 1.169 g of off-white solid was 
obtained.  This was recrystallized from EtOH/water to give 500 mg (48%) of white crystalline solid, 
and 305 mg (29%) of off-white solid containing minor impurities.  Total yield = 77%.  1H NMR 
(DMSO-d6) δ 10.90 (s, 1H), 8.99 (s, 1H), 7.54 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.6 Hz, 1H), 7.35 (d, J = 
8.4 Hz, 2H), 5.03 (d, J = 8.6 Hz, 1H), 1.37 (s, 9H); 13C NMR (DMSO-d6) δ 166.5, 157.1, 138.1, 131.1, 
129.3, 120.8, 78.5, 54.9, 28.1; m/z HRMS (TOF ES+) C13H17BrN2NaO4 [M+Na]+ calcd 367.0264; 
found 367.0255; LC-MS tR: 3.16 min; HPLC tR: 5.85 min, 95%. 
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4.2.51. tert-Butyl (3-(4-fluorophenyl)-1-(hydroxyamino)-1-oxopropan-2-yl)carbamate (9c) 
Methyl 3-(4-fluorophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (5c) (200 mg, 0.67 mmol) 
was converted to the corresponding hydroxamic acid according to General Procedure D, to give 91 mg 
(45%) of a white solid.  1H NMR (DMSO-d6) δ 10.61 (s, 1H), 8.85 (s, 1H), 7.30–7.23 (m, 2H), 7.13–
7.05 (m, 2H), 7.01 (d, J = 8.7 Hz, 1H), 3.98 (td, J = 9.5/9.5/5.1 Hz, 1H), 2.83 (dd, J = 13.6/5.0 Hz, 1H), 
2.74 (dd, J = 13.6/9.9 Hz, 1H), 1.29 (s, 9H); 13C NMR (DMSO-d6) δ 168.3, 161.0 (d, JCF = 241.3 Hz), 
155.1, 134.2 (d, JCF = 2.8 Hz), 131.0 (d, JCF = 8.0 Hz), 114.7 (d, JCF = 21.0 Hz), 77.9, 53.6, 36.9, 28.2; 
m/z HRMS (TOF ES-) C14H18FN2O4 [M-H]- calcd 297.1256; found 297.1271; LC-MS tR: 3.39 min; 
HPLC tR: 5.52 min, 95%. 
4.2.52. tert-Butyl (3-(4-bromophenyl)-1-(hydroxyamino)-1-oxopropan-2-yl)carbamate (9d) 
Methyl 3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (5d) (120 mg, 0.33 mmol) 
was converted to the corresponding hydroxamic acid according to General Procedure D, to give 70 mg 
(58%) of a white solid.  1H NMR (DMSO-d6) δ 10.62 (s, 1H), 8.86 (s, 1H), 7.46 (app. d, J = 8.3 Hz, 
2H), 7.20 (app. d, J = 8.3 Hz, 2H), 7.03 (d, J = 8.7 Hz, 1H), 3.99 (ddd, J = 9.4/5.2/5.2 Hz, 1H), 2.81 
(dd, J = 13.6/5.1 Hz, 1H), 2.73 (dd, J = 13.5/9.9 Hz, 1H), 1.30 (s, 9H); 13C NMR (DMSO-d6) δ 168.2, 
155.1, 137.5, 131.5, 130.9, 119.5, 78.0, 53.4, 37.0, 28.1; m/z HRMS (TOF ES+) C14H19BrN2NaO4 
[M+Na]+ calcd 381.0420; found 381.0413; LC-MS tR: 3.49 min; HPLC tR: 6.08 min, 95%. 
4.2.53. tert-Butyl (1-(hydroxyamino)-3-(4-iodophenyl)-1-oxopropan-2-yl)carbamate (9e) 
Methyl 3-(4-iodophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (5e) (300 mg, 0.74 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 220 mg 
(73%) of a white solid.  1H NMR (DMSO-d6) δ 10.61 (s, 1H), 8.85 (s, 1H), 7.62 (app. d, J = 8.2 Hz, 
2H), 7.06 (app. d, J = 8.2 Hz, 2H), 7.01 (d, J = 8.7 Hz, 1H), 3.98 (ddd, J = 9.3/9.3/5.2 Hz, 1H), 2.79 
(dd, J = 13.5/5.2 Hz, 1H), 2.70 (dd, J = 13.6/9.9 Hz, 1H), 1.30 (s, 9H); 13C NMR (DMSO-d6) δ 168.2, 
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155.1, 137.9, 136.8, 131.7, 92.2, 78.0, 53.4, 37.2, 28.2; m/z HRMS (TOF ES+) C14H19IN2NaO4 
[M+Na]+ calcd 429.0282; found 429.0282; LC-MS tR: 3.52 min; HPLC tR: 6.26 min, 95%. 
4.2.54. tert-Butyl (1-([1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)carbamate (9f) 
Methyl 2-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetate (7a) (142 mg, 0.42 mmol) 
was dissolved in MeOH (1 mL) at RT.  To this was added a solution of NH2OH.HCl (43 mg, 0.62 
mmol, 1.5 eq) and NaOH (50 mg, 1.25 mmol, 3 eq) in water (0.5 mL). The mixture was stirred at RT 
overnight. LC-MS analysis indicated the formation of both the desired hydroxamic acid, and the 
corresponding carboxylic acid (hydrolysis product).  The mixture was concentrated under reduced 
pressure, and the residue taken up in acidified water (20 mL, water acidified to ~pH 4 with 2M HCl
 (aq)) 
and extracted with EtOAc (3 x 10 mL).  The combined organic layers were washed with brine (10 mL) 
before concentration under reduced pressure.  The resulting residue was further purified by FCC 
(eluent MeOH/DCM 0:100 to 10:90) to give 2-([1,1'-biphenyl]-4-yl)-2-((tert-
butoxycarbonyl)amino)acetic acid as 101 mg of glassy solid, as the major product.  This was directly 
converted to the desired hydroxamic acid according the General Procedure E, using CDI (75 mg, 0.47 
mmol, 1.5 eq), NH2OH.HCl (43 mg, 0.62 mmol, 2 eq). After stirring for 60 h, LC-MS analysis 
indicated conversion was not complete, so NH2OH.HCl (22 mg, 1 eq) was added and stirring continued 
for a further overnight period.  The mixture was then worked up and purified as described, to give 34 
mg (24% based on ester, 32% based on acid) of white solid.  1H NMR (DMSO-d6) δ 10.92 (s, 1H), 8.98 
(d, J = 1.1 Hz, 1H), 7.70–7.57 (m, 4H), 7.57–7.40 (m, 5H), 7.39–7.32 (m, 1H), 5.10 (d, J = 8.7 Hz, 
1H), 1.60–1.11 (m, 9H); 13C NMR (DMSO-d6) δ 166.9, 154.9, 139.8, 139.5, 137.9, 128.9, 127.7, 
127.5, 126.7, 126.6, 78.4, 55.1, 28.2; m/z HRMS (TOF ES+) C19H22N2NaO4 [M+Na]+ calcd 365.1472; 
found 365.1469; LC-MS tR: 3.63 min; HPLC tR: 6.52 min, 98%. 
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4.2.55. tert-Butyl (1-(2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)carbamate (9g) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)acetate (7b) (150 mg, 0.42 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure D, to give 
118 mg (79%) of off-white solid.  1H NMR (DMSO-d6) δ 10.93 (s, 1H), 8.99 (s, 1H), 7.57–7.37 (m, 
7H), 7.36–7.25 (m, 2H), 5.12 (d, J = 8.7 Hz, 1H), 1.80–0.89 (m, 9H); 19F NMR (DMSO-d6) δ -118.46; 
13C NMR (DMSO-d6) δ 166.8, 159.1 (d, JCF = 245.7 Hz), 154.9, 138.4, 134.4, 130.8 (d, JCF = 3.2 Hz), 
129.6 (d, JCF = 8.2 Hz), 128.7 (d, JCF = 2.7 Hz), 127.9 (d, JCF = 13.1 Hz), 127.3, 125.0 (d, JCF = 3.4 
Hz), 116.1 (d, JCF = 22.5 Hz), 78.4, 55.2, 28.2; m/z HRMS (TOF ES+) C19H20FN2O4 [M-H]- calcd 
359.1413; found 359.1429; LC-MS tR: 3.63 min; HPLC tR: 6.55 min, > 99%. 
4.2.56. tert-Butyl (1-(3'-fluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)carbamate (9h) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(3'-fluoro-[1,1'-biphenyl]-4-yl)acetate (7c) (133 mg, 0.37 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure D.  
Initially only 31 mg of product was obtained from clean fractions after FCC.  Impure fractions were 
combined and diluted with PE.  Collection of the resulting precipitate by filtration (vacuum) gave a 
further 32 mg of off-white solid.  Overall, 63 mg (47%) of off-white solid were isolated.  1H NMR 
(DMSO-d6) δ 10.92 (s, 1H), 8.99 (d, J = 1.2 Hz, 1H), 7.67 (d, J = 8.3 Hz, 2H), 7.59–7.33 (m, 6H), 
7.31–7.02 (m, 1H), 5.11 (d, J = 8.7 Hz, 1H), 1.65–1.00 (m, 9H); 19F NMR (DMSO-d6) δ -112.85; 13C 
NMR (DMSO-d6) δ 166.8, 162.7 (d, JCF = 243.2 Hz), 155.8, 142.3 (d, JCF = 8.0 Hz), 138.6, 138.0 (d, 
JCF = 2.2 Hz), 130.9 (d, JCF = 8.5 Hz), 127.7, 126.7, 122.7 (d, JCF = 2.3 Hz), 114.2 (d, JCF = 20.8 Hz), 
113.4 (d, J = 22.0 Hz), 78.4, 55.1, 28.2; m/z HRMS (TOF ES+) C19H21FN2NaO4 [M+Na]+ calcd 
383.1378; found 383.1365; LC-MS tR: 3.65 min; HPLC tR: 6.62 min, 98%. 
4.2.57. tert-Butyl (1-(4'-fluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)carbamate (9i) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(4'-fluoro-[1,1'-biphenyl]-4-yl)acetate (7d) (149 mg, 0.41 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure D, to give 
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100 mg (67%) of off-white solid.  1H NMR (DMSO-d6) δ 10.91 (s, 1H), 8.98 (s, 1H), 7.74–7.65 (m, 
2H), 7.61 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.7 Hz, 1H), 7.34–7.22 (m, 2H), 
5.10 (d, J = 8.8 Hz, 1H), 1.61–1.00 (m, 9H); 19F NMR (DMSO-d6) δ -115.51; 13C NMR (DMSO-d6) δ 
166.9, 161.9 (d, JCF = 242.6 Hz), 154.9, 138.4, 136.3 (d, JCF = 2.9 Hz), 135.5, 128.7 (d, JCF = 8.2 Hz), 
127.7, 126.5, 115.7 (d, JCF = 21.4 Hz), 78.4, 55.1, 28.2; m/z HRMS (TOF ES+) C19H21FN2NaO4 
[M+Na]+ calcd 383.1378; found 383.1382; LC-MS tR: 3.59 min; HPLC tR: 6.60 min, 99%. 
4.2.58. tert-Butyl (2-(hydroxyamino)-2-oxo-1-(2'-(trifluoromethyl)-[1,1'-biphenyl]-4-
yl)ethyl)carbamate (9j) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(2'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)acetate (7e) (180 
mg, 0.44 mmol) was converted to the corresponding hydroxamic acid according to General Procedure 
D, to give 127 mg (71%) off-white glassy solid.  1H NMR (DMSO-d6) δ 10.96 (s, 1H), 9.03 (s, 1H), 
7.83 (d, J = 7.7 Hz, 1H), 7.71 (dd, J = 7.5/7.5 Hz, 1H), 7.61 (dd, J = 7.7/7.7 Hz, 1H), 7.55–7.43 (m, 
3H), 7.38 (d, J = 7.6 Hz, 1H), 7.28 (d, J = 8.0 Hz, 2H), 5.15 (d, J = 8.9 Hz, 1H), 1.66–1.13 (m, 9H); 19F 
NMR (DMSO-d6) δ -55.23; 13C NMR (DMSO-d6) δ 166.9, 155.0, 140.4, 138.5, 132.3, 132.2, 131.3, 
128.6, 128.1, 127.0, 126.6, 126.1 (q, JCF = 5.7 Hz), 124.2 (q, JCF = 273.9 Hz), 78.5, 55.1, 28.2; m/z 
HRMS (TOF ES+) C20H21F3N2NaO4 [M+Na]+ calcd 433.1346; found 433.1328; LC-MS tR: 3.70 min; 
HPLC tR: 6.99 min, 95%. 
4.2.59. tert-Butyl (2-(hydroxyamino)-2-oxo-1-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-
yl)ethyl)carbamate (9k) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)acetate (7f) (178 
mg, 0.43 mmol) was converted to the corresponding hydroxamic acid according to General Procedure 
D, to give 110 mg (62%) of off-white glassy solid.  1H NMR (DMSO-d6) δ 10.93 (s, 1H), 9.00 (s, 1H), 
8.05–7.91 (m, 2H), 7.80–7.66 (m, 4H), 7.53 (d, J = 8.3 Hz, 2H), 7.47 (d, J = 8.6 Hz, 1H), 5.12 (d, J = 
8.7 Hz, 1H), 1.39 (s, 9H); 19F NMR (DMSO-d6) δ -60.98; 13C NMR (DMSO-d6) δ 166.8, 155.0, 140.9, 
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138.8, 137.8, 130.8, 130.1, 129.8 (q, JCF = 31.6 Hz), 127.8, 126.9, 124.2 (q, JCF = 272.5 Hz), 124.1 (q, 
JCF = 3.7 Hz), 123.1 (q, JCF = 3.9 Hz), 78.5, 55.1, 28.2; m/z HRMS (TOF ES+) C20H21F3N2NaO4 
[M+Na]+ calcd 433.1346; found 433.1341; LC-MS tR: 3.72 min; HPLC tR: 7.15 min, 98%. 
4.2.60. tert-Butyl (2-(hydroxyamino)-2-oxo-1-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-
yl)ethyl)carbamate (9l) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)acetate (7g) 
(169 mg, 0.41 mmol) was converted to the corresponding hydroxamic acid according to General 
Procedure D.  Fractions obtained after FCC were found to contain minor impurities.  These were 
combined and diluted with PE. Collection of the resulting precipitate by filtration (vacuum) gave 68 mg 
(40%) of white solid.  1H NMR (DMSO-d6) δ 10.94 (s, 1H), 9.00 (s, 1H), 7.89 (d, J = 8.2 Hz, 2H), 7.81 
(d, J = 8.4 Hz, 2H), 7.71 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.7 Hz, 1H), 5.13 (d, 
J = 8.7 Hz, 1H), 1.39 (s, 9H); 19F NMR (DMSO-d6) δ -60.88; 13C NMR (DMSO-d6) δ 166.8, 155.0, 
143.8, 139.1, 137.9, 127.9 (q, JCF = 31.8 Hz), 127.8, 127.5, 127.0, 125.8 (q, JCF = 3.8 Hz), 124.3 (q, JCF 
= 255.0 Hz), 78.5, 55.1, 28.2; m/z HRMS (TOF ES+) C20H21F3N2NaO4 [M+Na]+ calcd 433.1346; found 
433.1356; LC-MS tR: 3.74 min; HPLC tR: 7.21 min, 97%. 
4.2.61. tert-Butyl (2-(hydroxyamino)-2-oxo-1-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yl)ethyl)carbamate 
(9m) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yl)acetate (7h) (152 
mg, 0.38 mmol) was converted to the corresponding hydroxamic acid according to General Procedure 
D, to give 105 mg (69%) of off-white solid.  1H NMR (DMSO-d6) δ 10.93 (s, 1H), 9.00 (d, J = 1.2 Hz, 
1H), 7.78–7.63 (m, 4H), 7.58–7.40 (m, 3H), 5.11 (d, J = 8.7 Hz, 1H), 1.38 (s, 9H); 19F NMR (DMSO-
d6) δ -134.93 (d, J = 21.7 Hz), -163.52 (dd, J = 21.7/21.7 Hz); 13C NMR (DMSO-d6) δ 166.7, 155.0, 
150.6 (ddd, JCF = 246.2/9.5/4.1 Hz), 139.2, 138.2 (dd, JCF = 248.9/15.7 Hz), 136.5 (dd, JCF = 8.2/3.6 
Hz), 136.1, 127.7, 126.7, 111.2 (d, JCF = 21.4 Hz), 78.5, 55.1, 28.2; m/z HRMS (TOF ES+) 
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C19H19F3N2NaO4 [M+Na]+ calcd 419.1189; found 419.1186; LC-MS tR: 3.70 min; HPLC tR: 6.99 min, 
96%. 
4.2.62. tert-Butyl (2-(hydroxyamino)-2-oxo-1-(4-(pyridin-3-yl)phenyl)ethyl)carbamate (9n) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-(pyridin-3-yl)phenyl)acetate (7i) (121 mg, 0.35 mmol) 
was converted to the corresponding hydroxamic acid according to General Procedure D, to give 23 mg 
(19%) of white solid.  1H NMR (DMSO-d6) δ 10.93 (s, 1H), 8.99 (s, 1H), 8.88 (s, 1H), 8.57 (d, J = 3.6 
Hz, 1H), 8.06 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.63–7.26 (m, 4H), 5.12 (d, J = 8.6 Hz, 
1H), 1.39 (s, 9H); 13C NMR (DMSO-d6) δ 166.8, 155.0, 148.5, 147.7, 138.7, 136.4, 134.1, 127.8, 
126.8, 123.9, 78.4, 55.1, 28.2; m/z HRMS (TOF ES+) C18H21N3O4 [MH]+ calcd 344.1605; found 
344.1611; LC-MS tR: 3.13 min; HPLC tR: 4.10 min, 99%. 
4.2.63. tert-Butyl (2-(hydroxyamino)-2-oxo-1-(4-(pyridin-4-yl)phenyl)ethyl)carbamate (9o) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-(pyridin-4-yl)phenyl)acetate (7j) (177 mg, 0.52 mmol) 
was converted to the corresponding hydroxamic acid according to General Procedure D, to give 77 mg 
(44%) of off-white solid.  1H NMR (DMSO-d6) δ 10.94 (s, 1H), 9.00 (d, J = 1.1 Hz, 1H), 8.63 (d, J = 
6.0 Hz, 2H), 7.78 (d, J = 8.3 Hz, 2H), 7.70 (dd, J = 4.6/1.6 Hz, 2H), 7.55 (d, J = 8.3 Hz, 2H), 7.50 (d, J 
= 8.7 Hz, 1H), 5.13 (d, J = 8.7 Hz, 1H), 1.39 (s, 9H); 13C NMR (DMSO-d6) δ 166.7, 155.0, 150.2, 
146.6, 139.9, 136.4, 127.9, 126.7, 121.2, 78.5, 55.2, 28.2; m/z HRMS (TOF ES+) C18H21N3O4 [MH]+ 
calcd 344.1605; found 344.1606; LC-MS tR: 3.11 min; HPLC tR: 4.13 min, 97%. 
4.2.64. tert-Butyl (2-(hydroxyamino)-2-oxo-1-(4-(thiophen-3-yl)phenyl)ethyl)carbamate (9p) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-(thiophen-3-yl)phenyl)acetate (7k) (129 mg, 0.37 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure D, to give 
94 mg (73%) of off-white solid.  1H NMR (DMSO-d6) δ 10.89 (s, 1H), 8.97 (s, 1H), 7.86 (dd, J = 
2.9/1.3 Hz, 1H), 7.67 (d, J = 8.3 Hz, 2H), 7.63 (dd, J = 5.0/2.9 Hz, 1H), 7.55 (dd, J = 5.0/1.3 Hz, 1H), 
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7.48–7.33 (m, 3H), 5.06 (d, J = 8.7 Hz, 1H), 1.77–0.68 (m, 9H); 13C NMR (DMSO-d6) δ 166.9, 154.9, 
141.1, 137.5, 134.5, 127.6, 127.1, 126.2, 125.9, 121.0, 78.4, 55.2, 28.2; m/z HRMS (TOF ES+) 
C17H20N2NaO4S [M+Na]+ calcd 371.1036; found 371.1019; LC-MS tR: 3.56 min; HPLC tR: 6.30 min, 
95%. 
4.2.65. tert-Butyl (2-(hydroxyamino)-1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-2-oxoethyl)carbamate 
(9q). 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)acetate (7l) (120 
mg, 0.35 mmol) was converted to the corresponding hydroxamic acid according to General Procedure 
D, to give 73 mg (61%) of white solid.  1H NMR (DMSO-d6) δ 10.85 (s, 1H), 8.95 (s, 1H), 8.11 (s, 
1H), 7.84 (d, J = 0.5 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.44–7.19 (m, 3H), 5.02 (d, J = 8.7 Hz, 1H), 
3.85 (s, 3H), 1.69–1.03 (m, 9H); 13C NMR (DMSO-d6) δ 167.0, 154.9, 136.2, 136.0, 132.0, 127.8, 
127.6, 124.7, 121.5, 78.4, 55.2, 38.7, 28.2; m/z HRMS (TOF ES+) C17H22N4O4 [MH]+ calcd 347.1714; 
found 347.1708; LC-MS tR: 3.30 min; HPLC tR: 5.04 min, > 99%. 
4.2.66. tert-Butyl (2-(hydroxyamino)-1-(3'-(N'-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)-2-
oxoethyl)carbamate (9r) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(3'-cyano-[1,1'-biphenyl]-4-yl)acetate (7m) (153 mg, 0.42 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure D, to give 
91 mg (54%) of white solid.  1H NMR (DMSO-d6) δ 10.92 (s, 1H), 9.67 (s, 1H), 8.99 (s, 1H), 7.92 (s, 
1H), 7.76–7.61 (m, 4H), 7.58–7.37 (m, 4H), 5.92 (s, 2H), 5.10 (d, J = 8.7 Hz, 1H), 1.64–1.10 (m, 9H); 
13C NMR (DMSO-d6) δ 166.9, 155.0, 150.7, 139.7, 139.3, 138.1, 134.0, 128.7, 127.7, 127.1, 126.6, 
124.5, 123.7, 78.4, 55.2, 28.2; m/z HRMS (TOF ES+) C20H24N4O5 [MH]+ calcd 401.1819; found 
401.1816; LC-MS tR: 3.17 min; HPLC tR: 4.57 min, 95%. 
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4.2.67. tert-Butyl (2-(hydroxyamino)-1-(4'-(N'-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)-2-
oxoethyl)carbamate (9s) 
Methyl 2-((tert-butoxycarbonyl)amino)-2-(4'-cyano-[1,1'-biphenyl]-4-yl)acetate (7n) (152 mg, 0.41 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure D, to give 
67 mg (40%) of white solid.  1H NMR (DMSO-d6) δ 10.92 (s, 1H), 9.68 (s, 1H), 8.99 (d, J = 1.2 Hz, 
1H), 7.85–7.59 (m, 6H), 7.60–7.28 (m, 3H), 5.85 (s, 2H), 5.10 (d, J = 8.7 Hz, 1H), 1.36 (d, J = 21.7 Hz, 
9H); 13C NMR (DMSO-d6) δ 166.9, 155.0, 150.5, 140.1, 138.8, 138.1, 132.4, 127.7, 126.5, 126.3, 
125.9, 78.4, 55.2, 28.2; m/z HRMS (TOF ES+) C20H24N4O5 [MH]+ calcd 401.1819; found 401.1815; 
LC-MS tR: 3.16 min; HPLC tR: 4.47 min, 95%. 
4.2.68. tert-Butyl (3-([1,1'-biphenyl]-4-yl)-1-(hydroxyamino)-1-oxopropan-2-yl)carbamate (9t) 
Methyl 3-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)propanoate (7o) (119 mg, 0.33 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure D, to give 
75 mg (63%) of white solid.  1H NMR (DMSO-d6) δ 10.65 (s, 1H), 8.87 (s, 1H), 7.68–7.61 (m, 2H), 
7.57 (app. d, J = 8.2 Hz, 2H), 7.48–7.42 (m, 2H), 7.37–7.31 (m, 3H), 7.05 (d, J = 8.6 Hz, 1H), 4.06 
(ddd, J = 9.3/9.3/5.1 Hz, 1H), 2.89 (dd, J = 13.7/5.0 Hz, 1H), 2.80 (dd, J = 13.6/9.9 Hz, 1H), 1.30 (s, 
9H); 13C NMR (DMSO-d6) δ 168.5, 155.2, 140.0, 138.1, 137.4, 129.8, 128.9, 127.2, 126.5, 126.4, 78.0, 
53.6, 37.3, 28.2; m/z HRMS (TOF ES+) C20H24N2NaO4 [M+Na]+ calcd 379.1628; found 379.1619; LC-
MS tR: 3.60 min; HPLC tR: 6.65 min, > 99%. 
4.2.69. tert-Butyl (1-(hydroxyamino)-3-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-1-oxopropan-2-
yl)carbamate (9u) 
Methyl 2-((tert-butoxycarbonyl)amino)-3-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)propanoate (7p) 
(119 mg, 0.33 mmol) was converted to the corresponding hydroxamic acid according to General 
Procedure D, to give 57 mg (48%) of white solid.  1H NMR (DMSO-d6) δ 10.61 (s, 1H), 8.85 (d, J = 
1.4 Hz, 1H), 8.08 (s, 1H), 7.81 (d, J = 0.7 Hz, 1H), 7.45 (app. d, J = 8.1 Hz, 2H), 7.21 (app. d, J = 8.2 
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Hz, 2H), 6.99 (d, J = 8.6 Hz, 1H), 4.01 (ddd, J = 9.1/9.1/5.4 Hz, 1H), 3.85 (s, 3H), 2.82 (dd, J = 
13.7/5.1 Hz, 1H), 2.74 (dd, J = 13.6/9.7 Hz, 1H), 1.30 (s, 9H); 13C NMR (DMSO-d6) δ 168.5, 155.1, 
135.9, 135.7, 130.6, 129.6, 127.5, 124.7, 121.8, 77.9, 53.6, 38.6, 37.4, 28.2; m/z HRMS (TOF ES+) 
C18H24N4O4 [MH]+ calcd 360.1792; found 360.1781; LC-MS tR: 3.30 min; HPLC tR: 5.07 min, 97%. 
4.2.70. N-(1-(4-Fluorophenyl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10a) 
Methyl 2-(4-fluorophenyl)-2-pivalamidoacetate (6a) (200 mg, 0.71 mmol) was converted to the 
corresponding hydroxamic acid according to General Procedure D, to give 141 mg (70%) of white 
solid.  1H NMR (DMSO-d6) δ 10.98 (s, 1H), 9.05 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.47–7.40 (m, 2H), 
7.21–7.14 (m, 2H), 5.37 (d, J = 8.1 Hz, 1H), 1.13 (s, 9H); 13C NMR (DMSO-d6) δ 176.9, 166.6, 161.6 
(d, JCF = 243.2 Hz), 135.2 (d, JCF = 3.0 Hz), 128.8 (d, JCF = 8.3 Hz), 115.0 (d, JCF = 21.4 Hz), 53.0, 
38.1, 27.2; m/z HRMS (TOF ES+) C13H17FN2O3 [MH]+ calcd 269.1296; found 269.1294; LC-MS tR: 
3.32 min; HPLC tR: 4.87 min, 95%. 
4.2.71. N-(1-(4-Bromophenyl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10b) 
Methyl 2-(4-bromophenyl)-2-pivalamidoacetate (6b) (50 mg, 0.15 mmol) was converted to the 
corresponding hydroxamic acid according to General Procedure D, to give 31 mg (62%) of white solid.  
1H NMR (DMSO-d6) δ 11.00 (s, 1H), 9.07 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.57–7.52 (m, 2H), 7.38–
7.32 (m, 2H), 5.34 (d, J = 8.0 Hz, 1H), 1.13 (s, 9H); 13C NMR (DMSO-d6) δ 176.9, 166.3, 138.5, 
131.2, 129.1, 120.7, 53.2, 38.1, 27.1; m/z HRMS (TOF ES+) C13H17BrN2O3 [MH]+ calcd 329.0495; 
found 329.0499; LC-MS tR: 3.43 min; HPLC tR: 5.48 min, 95%. 
4.2.72. 3-(4-Fluorophenyl)-N-hydroxy-2-pivalamidopropanamide (10c) 
Methyl 3-(4-fluorophenyl)-2-pivalamidopropanoate (6c) (100 mg, 0.36 mmol) was converted to the 
corresponding hydroxamic acid according to General Procedure D, to give 67 mg (67%) of white solid.  
1H NMR (DMSO-d6) δ 10.64 (s, 1H), 8.88 (s, 1H), 7.43 (d, J = 8.7 Hz, 1H), 7.31–7.21 (m, 2H), 7.11–
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7.02 (m, 2H), 4.39 (ddd, J = 8.5/8.5/6.7 Hz, 1H), 2.95–2.82 (m, 2H), 0.98 (s, 9H); 13C NMR (DMSO-
d6) δ 177.0, 168.2, 160.9 (d, JCF = 241.4 Hz), 134.2 (d, JCF = 3.0 Hz), 131.1 (d, JCF = 8.0 Hz), 114.6 (d, 
JCF = 21.0 Hz), 51.7, 38.0, 36.7, 27.2; m/z HRMS (TOF ES+) C14H19FN2O3 [MH]+ calcd 283.1452; 
found 283.1461; LC-MS tR: 3.36 min; HPLC tR: 5.52 min, 95%. 
4.2.73. 3-(4-Bromophenyl)-N-hydroxy-2-pivalamidopropanamide (10d) 
Methyl 3-(4-bromophenyl)-2-pivalamidopropanoate (6d) (120 mg, 0.35 mmol) was converted to the 
corresponding hydroxamic acid according to General Procedure D, to give 76 mg (63%) of white solid.  
1H NMR (DMSO-d6) δ 10.64 (br. s, 1H), 8.89 (br. s, 1H), 7.49–7.41 (m, 3H), 7.22–7.16 (m, 2H), 4.40 
(ddd, J = 8.8/8.8/6.1 Hz, 1H), 2.91–2.83 (m, 2H), 0.98 (s, 9H); 13C NMR (DMSO-d6) δ 177.0, 168.1, 
137.5, 131.6, 130.8, 119.4, 51.5, 38.0, 36.9, 27.2; m/z HRMS (TOF ES+) C14H19BrN2O3 [MH]+ calcd 
343.0652; found 343.0645; LC-MS tR: 3.43 min; HPLC tR: 5.76 min, 95%. 
4.2.74. N-Hydroxy-3-(4-iodophenyl)-2-pivalamidopropanamide (10e) 
Methyl 3-(4-iodophenyl)-2-pivalamidopropanoate (6e) (300 mg, 0.77 mmol) was converted to the 
corresponding hydroxamic acid according to General Procedure D, to give 180 mg (60%) of white 
solid.  1H NMR (DMSO-d6) δ 10.64 (s, 1H), 8.88 (s, 1H), 7.60 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 8.6 Hz, 
1H), 7.05 (d, J = 8.1 Hz, 2H), 4.42–4.32 (m, 1H), 2.90–2.78 (m, 2H), 0.99 (s, J = 3.8 Hz, 9H); 13C 
NMR (DMSO-d6) δ 177.0, 168.0, 137.9, 136.7, 131.8, 92.1, 51.5, 38.0, 37.1, 27.2; m/z HRMS (TOF 
ES+) C14H19IN2O3 [MH]+ calcd 391.0513; found 391.0498; LC-MS tR: 3.48 min; HPLC tR: 5.95 min, 
95%. 
4.2.75. N-(1-([1,1'-Biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10f) 
Methyl 2-([1,1'-biphenyl]-4-yl)-2-pivalamidoacetate  (8a) (100 mg, 0.30 mmol) was converted to 
the corresponding hydroxamic acid according to General Procedure D, to give 64 mg (64%) of white 
solid.  1H NMR (DMSO-d6) δ 11.01 (s, 1H), 9.06 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.68–7.60 (m, 4H), 
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7.53–7.42 (m, 4H), 7.39–7.33 (m, 1H), 5.41 (d, J = 8.1 Hz, 1H), 1.15 (s, 9H); 13C NMR (DMSO-d6) δ 
176.9, 166.7, 139.8, 139.4, 138.2, 128.9, 127.5, 127.4, 126.7, 126.6, 53.5, 38.2, 27.2; m/z HRMS (TOF 
ES+) C19H22N2O3 [MH]+ calcd 327.1703; found 327.1702; LC-MS tR: 3.51 min; HPLC tR: 6.19 min, 
98%. 
4.2.76. N-(1-(2'-Fluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10g) 
Methyl 2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8b) (112 mg, 0.33 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 85 mg 
(76%) of white solid.  1H NMR (DMSO-d6) δ 11.03 (s, 1H), 9.07 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 
7.56–7.48 (m, 5H), 7.46–7.38 (m, 1H), 7.34–7.26 (m, 2H), 5.42 (d, J = 8.0 Hz, 1H), 1.16 (s, 9H); 19F 
NMR (d6-DMSO) δ -118.5; 13C NMR (DMSO-d6) δ 176.9, 166.7, 159.1 (d, JCF = 245.7 Hz), 138.7, 
134.3, 130.8 (d, JCF = 3.3 Hz), 129.6 (d, JCF = 8.3 Hz), 128.7 (d, JCF = 2.7 Hz), 127.9 (d, JCF = 13.2 
Hz), 127.1, 125.0 (d, JCF = 3.5 Hz), 116.1 (d, JCF = 22.5 Hz), 53.6, 38.2, 27.2; m/z HRMS (TOF ES+) 
C19H21FN2O3 [MH]+ calcd 345.1609; found 345.1609; LC-MS tR: 3.52 min; HPLC tR: 6.25 min, 96%. 
4.2.77. N-(1-(3'-Fluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10h) 
Methyl 2-(3'-fluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8c) (71 mg, 0.21 mmol) was 
converted to the corresponding hydroxamic acid compound according to General Procedure D, to give 
45 mg (62%) of white solid.  1H NMR (DMSO-d6) δ 11.03 (s, 1H), 9.07 (s, 1H), 7.76 (d, J = 8.1 Hz, 
1H), 7.71–7.65 (m, 2H), 7.55–7.46 (m, 5H), 7.23–7.15 (m, 1H), 5.42 (d, J = 8.1 Hz, 1H), 1.15 (s, 9H); 
19F NMR (d6-DMSO) δ -112.8; 13C NMR (DMSO-d6) δ 176.9, 166.6, 162.7 (d, JCF = 243.3 Hz), 142.3 
(d, JCF = 7.8 Hz), 138.9, 138.0 (d, JCF = 2.2 Hz), 130.9 (d, JCF = 8.6 Hz), 127.4, 126.8, 122.7 (d, JCF = 
2.6 Hz), 114.2 (d, JCF = 21.0 Hz), 113.4 (d, JCF = 22.0 Hz), 53.5, 38.2, 27.2; m/z HRMS (TOF ES+) 
C19H21FN2O3 [MH]+ calcd 345.1609; found 345.1613; LC-MS tR: 3.53 min; HPLC tR: 6.32 min, 96%. 
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4.2.78. N-(1-(4'-Fluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10i) 
Methyl 2-(4'-fluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8d) (99 mg, 0.29 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 83 mg 
(83%) of white solid.  1H NMR (DMSO-d6) δ 10.99 (s, 1H), 9.06 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 
7.72–7.65 (m, 2H), 7.62 (app. d, J = 8.4 Hz, 2H), 7.48 (app. d, J = 8.3 Hz, 2H), 7.32–7.25 (m, 2H), 
5.41 (d, J = 8.1 Hz, 1H), 1.15 (s, 9H); 19F NMR (DMSO-d6) δ -115.47; 13C NMR (DMSO-d6) δ 176.9, 
166.7, 161.9 (d, JCF = 244.3 Hz), 138.4, 138.2, 136.3 (d, JCF = 3.1 Hz), 128.7 (d, JCF = 8.1 Hz), 127.4, 
126.6, 115.7 (d, JCF = 21.3 Hz), 53.5, 38.2, 27.2; m/z HRMS (TOF ES+) C19H21FN2O3 [MH]+ calcd 
345.1609; found 345.1613; LC-MS tR: 3.52 min; HPLC tR: 6.30 min, 95%.   
4.2.79. N-(1-(2',4'-Difluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10j) 
Methyl 2-(2',4'-difluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8e) (86 mg, 0.24 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 48 mg 
(55%) of white solid.  1H NMR (DMSO-d6) δ 11.04 (s, 1H), 9.08 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 
7.61–7.46 (m, 6H), 7.36 (ddd, J = 11.7/9.4/2.6 Hz, 1H), 7.23–7.15 (m, 1H), 5.42 (d, J = 8.0 Hz, 1H), 
1.15 (s, 9H); 19F NMR (DMSO-d6) δ -111.1 (d, J = 7.5 Hz), -113.8 (d, J = 7.5 Hz); 13C NMR (DMSO-
d6) δ 176.9, 166.6, 161.7 (dd, JCF = 246.8, 12.2 Hz), 159.1 (dd, JCF  = 248.6/12.4 Hz), 138.8, 133.5, 
131.9 (dd, JCF = 9.7/4.8 Hz), 128.7 (d, JCF = 2.4 Hz), 127.1, 124.6 (dd, JCF = 13.5/3.7 Hz), 112.1 (dd, 
JCF = 21.1/3.6 Hz), 104.5 (dd, JCF = 26.7/26.1 Hz), 53.6, 38.2, 27.2; m/z HRMS (TOF ES+) 
C19H20F2N2O3 [MH]+ calcd 363.1515; found 363.1518; LC-MS tR: 3.55 min; HPLC tR: 6.41 min, > 
99%. 
4.2.80. N-(1-(2',6'-Difluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10k) 
Methyl 2-(2',6'-difluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8f) (72 mg, 0.20 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 49 mg 
(69%) of white solid.  1H NMR (DMSO-d6) δ 11.05 (s, 1H), 9.09 (s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 
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7.57–7.39 (m, 5H), 7.26–7.17 (m, 2H), 5.43 (d, J = 8.0 Hz, 1H), 1.16 (s, 9H); 19F NMR (DMSO-d6) 
δ -114.8; 13C NMR (CDCl3) δ 177.0, 166.6, 159.4 (dd, JCF = 246.5/7.1 Hz), 139.3, 131.4–128.9 (m), 
127.7, 126.9, 117.4 (dd, JCF = 19.2/19.2 Hz), 113.4–110.4 (m), 53.6, 38.2, 27.2; m/z HRMS (TOF ES+) 
C19H20F2N2O3 [MH]+ calcd 363.1515; found 363.1509; LC-MS tR: 3.50 min; HPLC tR: 6.26 min, 96%. 
4.2.81. N-(1-(3',4'-Difluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10l) 
Methyl 2-(3',4'-difluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8g) (150 mg, 0.40 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 91 mg 
(64%) of white solid.  1H NMR (DMSO-d6) δ 11.03 (s, 1H), 9.08 (s, 1H), 7.81–7.72 (m, 2H), 7.66 (d, J 
= 8.3 Hz, 2H), 7.55–7.46 (m, 4H), 5.42 (d, J = 8.1 Hz, 1H), 1.15 (s, 9H); 19F NMR (DMSO-d6) δ -138.2 
(d, J = 22.5 Hz), -140.8 (d, J = 22.5 Hz); 13C NMR (DMSO-d6) δ 176.9, 166.6, 149.8 (dd, JCF = 
245.1/12.7 Hz), 149.1 (dd, JCF = 246.1/12.6 Hz), 138.8, 137.5 (dd, JCF = 6.2/3.6 Hz), 137.2, 127.5, 
126.7, 123.4 (dd, JCF = 6.4/3.2 Hz), 117.9 (d, JCF = 17.0 Hz), 115.7 (d, JCF = 17.7 Hz), 53.5, 38.2, 27.2; 
m/z HRMS (TOF ES+) C19H20F2N2O3 [MH]+ calcd 363.1515; found 363.1515; LC-MS tR: 3.54 min; 
HPLC tR: 6.47 min, > 99%. 
4.2.82. N-(1-(3',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10m) 
Methyl 2-(3',5'-difluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8h) (83 mg, 0.23 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 57 mg 
(68%) of white solid.  1H NMR (DMSO-d6) δ 11.03 (s, 1H), 9.08 (s, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.73 
(d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.3 Hz, 2H), 7.48–7.39 (m, 2H), 7.22 (dddd, J = 11.6/4.5/2.3/2.3 Hz, 
1H), 5.43 (d, J = 8.1 Hz, 1H), 1.15 (s, 9H); 19F NMR (DMSO-d6) δ -109.5; 13C NMR (DMSO-d6) δ 
176.9, 166.6, 162.9 (dd, JCF = 245.5/13.7 Hz), 143.4, 139.6, 136.8, 127.5, 126.8, 110.1–109.5 (m), 
102.7 (dd, JCF = 26.0/26.0 Hz), 53.5, 38.2, 27.2; m/z HRMS (TOF ES+) C19H20F2N2O3 [MH]+ calcd 
363.1515; found 363.1528; LC-MS tR: 3.57 min; HPLC tR: 6.51 min, 97%. 
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4.2.83. N-(1-(2',4’,6'-Trifluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)pivalamide (10n) 
Methyl 2-pivalamido-2-(2',4',6'-trifluoro-[1,1'-biphenyl]-4-yl)acetate (8i) (105 mg, 0.28 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 58 mg 
(55%) of white solid.  1H NMR (DMSO-d6) δ 11.03 (s, 1H), 9.07 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.52 
(d, J = 8.2 Hz, 2H), 7.41 (d, J = 8.2 Hz, 2H), 7.38–7.27 (m, 2H), 5.43 (d, J = 8.0 Hz, 1H), 1.16 (s, J = 
7.5 Hz, 9H); 19F NMR (DMSO-d6) δ -108.6 (dd, J = 6.1/6.1 Hz), -111.7 (d, J = 6.2 Hz); 13C NMR 
(DMSO-d6) δ 177.0, 166.6, 162.6 (d, JCF = 16.4 Hz), 160.2, 159.6 (ddd, JCF = 25.7/15.3/9.9 Hz), 139.4, 
130.1, 127.0, 114.3 (d, JCF = 4.8 Hz), 102.3 – 99.9 (m), 53.6, 38.2, 27.2; m/z HRMS (TOF ES+) 
C19H19F3N2O3 [MH]+ calcd 381.1421; found 381.1419; LC-MS tR: 3.53 min; HPLC tR: 6.25 min, 99%. 
4.2.83. N-(2-(Hydroxyamino)-2-oxo-1-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yl)ethyl)pivalamide (10o) 
Methyl 2-pivalamido-2-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yl)acetate (8j) (50 mg, 0.13 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 44 mg 
(88%) of white solid.  1H NMR (DMSO-d6) δ 11.02 (s, 1H), 9.07 (s, 1H), 7.78 (d, J = 8.1 Hz, 1H), 
7.74–7.65 (m, 4H), 7.50 (d, J = 8.3 Hz, 2H), 5.42 (d, J = 8.1 Hz, 1H), 1.15 (s, 9H); 19F NMR (DMSO-
d6) δ -134.74 (d, J = 21.7 Hz), -163.41 (dd, J = 21.7/21.7 Hz); 13C NMR (DMSO-d6) δ 176.9, 166.5, 
150.6 (ddd, JCF = 14.0/9.5/4.0 Hz), 139.5, 136.7–136.4 (m), 136.2–136.0 (m), 127.5, 126.8, 111.5–
110.7 (m), 53.5, 38.2, 27.2; m/z HRMS (TOF ES+) C19H19F3N2O3 [MH]+ calcd 381.1421; found 
381.1425; LC-MS tR: 3.60 min; HPLC tR: 6.71 min, 98%. 
4.2.84. N-(1-(2',3’,4’,5’,6'-Pentafluoro-[1,1'-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl) pivalamide 
(10p) 
Methyl 2-(2',3',4',5',6'-pentafluoro-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8k) (92 mg, 0.22 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure D, to give 
50 mg (55%) of white solid.  1H NMR (DMSO-d6) δ 11.12 (s, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.55 (d, J 
= 8.3 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 5.42 (d, J = 7.9 Hz, 1H), 1.14 (s, 9H); 19F NMR (DMSO-d6) δ -
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
143.5 (dd, J = 24.8/7.7 Hz), -156.0 (dd, J = 22.3/22.3 Hz), -162.5–-162.7 (m); 13C NMR (DMSO-d6) δ 
177.5, 166.7, 145.3–142.5 (m), 141.5–138.6 (m), 138.9–136.1 (m), 130.4, 127.5, 125.3, 115.6–115.0 
(m), 53.9, 38.4, 27.4;  m/z HRMS (TOF ES+) C19H17F5N2O3 [MH]+ calcd 417.1232; found 417.1244; 
LC-MS tR: 3.61 min; HPLC tR: 5.95 min, 95%. 
4.2.85. N-(2-(Hydroxyamino)-2-oxo-1-(4-(thiophen-3-yl)phenyl)ethyl)pivalamide (10q) 
Methyl 2-pivalamido-2-(4-(thiophen-3-yl)phenyl)acetate (8l) (89 mg, 0.27 mmol) was converted to 
the corresponding hydroxamic acid according to General Procedure D, to give 82 mg (91%) of white 
solid.  1H NMR (DMSO-d6) δ 11.00 (s, 1H), 9.05 (s, 1H), 7.86 (dd, J = 2.9/1.3 Hz, 1H), 7.72 (d, J = 8.1 
Hz, 1H), 7.70–7.66 (m, 2H), 7.63 (dd, J = 5.0/2.9 Hz, 1H), 7.55 (dd, J = 5.0/1.3 Hz, 1H), 7.43 (app. d, J 
= 8.2 Hz, 2H), 5.38 (d, J = 8.1 Hz, 1H), 1.15 (s, 9H); 13C NMR (DMSO-d6) δ 176.8, 166.7, 141.1, 
137.8, 134.4, 127.3, 127.1, 126.2, 126.0, 121.0, 53.5, 38.2, 27.2; m/z HRMS (TOF ES+) C17H20N2O3S 
[MH]+ calcd 333.1267; found 333.1266; LC-MS tR: 3.48 min; HPLC tR: 6.02 min, > 99%. 
4.2.86. N-(2-(Hydroxyamino)-1-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-2-oxoethyl)pivalamide (10r) 
Methyl 2-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-2-pivalamidoacetate (8m) (81 mg, 0.24 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 52 mg 
(66%) of white solid.  1H NMR (DMSO-d6) δ 10.89 (s, 1H), 9.03 (s, 1H), 8.11 (s, 1H), 7.84 (s, 1H), 
7.67 (d, J = 8.0 Hz, 1H), 7.52 (app. d, J = 8.1 Hz, 2H), 7.36 (app. d, J = 8.1 Hz, 2H), 5.34 (d, J = 8.0 
Hz, 1H), 3.85 (s, 3H), 1.14 (s, 9H); 13C NMR (DMSO-d6) δ 176.8, 166.8, 136.5, 136.0, 131.9, 127.8, 
127.3, 124.8, 121.5, 53.5, 38.7, 38.1, 27.2; m/z HRMS (TOF ES+) C17H22N4O3 [MH]+ calcd 331.1765; 
found 331.1765; LC-MS tR: 3.26 min; HPLC tR: 4.71 min, > 99%. 
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4.2.87. N-(2-(Hydroxyamino)-1-(3'-(N'-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)-2-
oxoethyl)pivalamide (10s) 
Methyl 2-(3'-cyano-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8n) (121 mg, 0.35 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 78 mg 
(58%) of white solid.  1H NMR (DMSO-d6) δ 11.02 (s, 1H), 9.66 (s, 1H), 9.07 (s, 1H), 7.94–7.91 (m, 
1H), 7.75 (d, J = 8.1 Hz, 1H), 7.71–7.63 (m, 4H), 7.51 (app. d, J = 8.3 Hz, 2H), 7.45 (t, J = 7.8 Hz, 
1H), 5.92 (s, 2H), 5.42 (d, J = 8.0 Hz, 1H), 1.16 (s, 9H); 13C NMR (DMSO-d6) δ 176.9, 166.7, 150.7, 
139.7, 139.2, 138.4, 134.0, 128.8, 127.4, 127.1, 126.7, 124.5, 123.7, 53.5, 38.2, 27.2; m/z HRMS (TOF 
ES+) C20H24N4O4 [MH]+ calcd 385.1870; found 385.1870; LC-MS tR: 3.19 min; HPLC tR: 4.28 min, 
95%. 
4.2.88. N-(2-(Hydroxyamino)-1-(4'-(N'-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)-2-
oxoethyl)pivalamide (10t) 
Methyl 2-(4'-cyano-[1,1'-biphenyl]-4-yl)-2-pivalamidoacetate (8o) (62 mg, 0.18 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure D, to give 15 mg 
(22%) of white solid.  1H NMR (DMSO-d6) δ 11.01 (s, 1H), 9.68 (s, 1H), 9.06 (s, 1H), 7.79–7.72 (m, 
3H), 7.70–7.64 (m, 4H), 7.49 (app. d, J = 8.3 Hz, 2H), 5.84 (br. s, 2H), 5.41 (d, J = 8.0 Hz, 1H), 1.15 
(s, 9H); 13C NMR (DMSO-d6) δ 176.9, 166.7, 150.5, 140.1, 138.8, 138.4, 132.4, 127.4, 126.5, 126.3, 
125.9, 53.5, 38.2, 27.2; m/z HRMS (TOF ES+) C20H24N4O4 [MH]+ calcd 385.1870; found 385.1883; 
LC-MS tR: 3.16 min; HPLC tR: 4.18 min, 95%. 
4.2.89. 3-([1,1'-Biphenyl]-4-yl)-N-hydroxy-2-pivalamidopropanamide (10u) 
Methyl 3-([1,1'-biphenyl]-4-yl)-2-pivalamidopropanoate  (8p) (92 mg, 0.27 mmol) was converted to 
the corresponding hydroxamic acid according to General Procedure D, to give 50 mg (54%) of white 
solid.  1H NMR (DMSO-d6) δ 10.66 (s, 1H), 8.89 (s, 1H), 7.66–7.60 (m, 2H), 7.56 (app. d, J = 8.3 Hz, 
2H), 7.49–7.41 (m, 3H), 7.37–7.30 (m, 3H), 4.49–4.41 (m, 1H), 3.00–2.90 (m, 2H), 1.00 (s, 9H); 13C 
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NMR (DMSO-d6) δ 177.0, 168.2, 140.0, 138.0, 137.4, 129.9, 128.9, 127.2, 126.5, 126.2, 51.7, 38.0, 
37.2, 27.2; m/z HRMS (TOF ES+) C20H24N2O3 [MH]+ calcd 341.1860; found 341.1862; LC-MS tR: 
3.54 min; HPLC tR: 6.35 min, > 99%. 
4.2.90. N-Hydroxy-3-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-2-pivalamidopropanamide (10v) 
Methyl 3-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-2-pivalamidopropanoate (8q) (85 mg, 0.25 mmol) 
was converted to the corresponding hydroxamic acid according to General Procedure D, to give 59 mg 
(69%) of white solid.  1H NMR (DMSO-d6) δ 10.64 (s, 1H), 8.88 (d, J = 0.9 Hz, 1H), 8.07 (s, 1H), 7.81 
(d, J = 0.7 Hz, 1H), 7.46–7.38 (m, 3H), 7.20 (app. d, J = 8.2 Hz, 2H), 4.45–4.37 (m, 1H), 3.84 (s, 3H), 
2.88 (d, J = 7.4 Hz, 2H), 0.99 (s, 9H); 13C NMR (DMSO-d6) δ 177.0, 168.3, 135.9, 135.6, 130.6, 129.7, 
127.6, 124.5, 121.8, 51.8, 38.6, 38.0, 37.3, 27.2; m/z HRMS (TOF ES+) C18H24N4O3 [MH]+ calcd 
345.1921; found 345.1909; LC-MS tR: 3.27 min; HPLC tR: 4.72 min, > 99%.  
4.3. Biochemistry 
4.3.1. Preparation of recombinant PfA-M1 and PfA-M17 
The production of recombinant malaria neutral aminopeptidases PfA-M1 and PfA-M17 was 
undertaken in Escherichia coli and proteins purified using a two-step purification process of Ni-NTA-
agarose column followed by size exclusion chromatography on a Superdex 200 16/60 using an 
AKTAxpress high throughput chromatography system 
(http://proteinexpress.med.monash.edu.au/index.htm) as described previously [9, 12].  Biochemical 
analysis indicated that kinetic parameters (kcat, Km, kcat/Km) of material purified and used in subsequent 
crystallization trials were the same as published. 
4.3.2. Enzymatic analysis 
Aminopeptidase assays were based on previously published protocols [8].  Briefly, the activity of 
both enzymes was determined by measuring the release of the fluorogenic leaving group, NHMec, 
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from the fluorogenic peptide L-Leucine-7-amido-4-methylcoumarin hydrochloride (H-Leu-NHMec) 
(Sigma L2145). The reactions were carried out in 384-well microtitre plates, 50 µL total volume at 
37°C using a spectrofluorimeter (BMG FLUOstar) with excitation at 355 nm and emission at 460 nm. 
PfA-M1 was pre-incubated in 100 mM Tris pH 8.0 at 37°C and PfA-M17 in 50 mM Tris pH 8.0, 2 mM 
CoCl2, with the inhibitors for 10 min prior to the addition of substrate.  Inhibitor concentrations were 
assayed between 500pM – 500 µM. The fluorescence signal was monitored until a final steady state 
velocity, V, was obtained.  The Ki values were then evaluated using Dixon plots of 1/V versus inhibitor 
concentration in which the substrate concentration was maintained below the Km of the enzyme. 
Statistical analysis including point of intersection (-Ki) and graphical output was performed in 
GraphPad Prism® 6. Representative Dixon plots of selected inhibitors can be found in Supp Fig 8. 
4.3.3. Crystallisation and X-ray Data Collection 
Nine PfA-M1 co-crystal structures (with compounds 9b, 9f, 9m, 9q, 9r, 10b, 10o, 10q, 10s), and six 
PfA-M17 co-crystal structures (with compounds 9b, 10b, 10o, 10q, 10r, 10s) were determined in this 
study.  A summary of statistics is provided in Supplementary Table 1, 2 and 3.  Crystals of the PfA-M1 
bound complexes were obtained by co-crystallization of each compound with PfA-M1 in mother liquor 
containing 1 mM ligand.  For PfA-M17 bound complexes, prior to data collection, crystals were soaked 
in mother liquor containing 1 mM ligand and 1 mM ZnSO4.  Data were collected at 100 K using 
synchrotron radiation at the Australian Synchrotron using the macro crystallography MX1 beamline 
3BM1 [32] for PfA-M1 and the micro crystallography MX2 beamline 3ID1 for PfA-M17.  Diffraction 
images were processed and integrated using iMosflm [33] (PfA-M1) or XDS [34] (PfA-M17), scaled 
using Aimless [35] and solved by molecular replacement using Phaser [36] as part of the CCP4 suite 
[37].  The structures were refined using iterative cycles of PHENIX [38], with 5% of reflections set 
aside from refinement for calculation of RFree.  Between refinement cycles, the protein structure, 
solvent and inhibitors were was manually built into 2Fo–Fc and Fo–Fc electron density maps using 
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COOT [39], with restraint files generated by the PRODRG2 Server [40] where necessary.  The 
coordinates and structure factors are available from the Protein Data Bank with PDB Accession codes, 
PfA-M1: 9b (4ZW3), 9f (4ZW5), 9q (4ZW6), 9m (4ZW7), 9r (4ZW8), 10b (4ZX3), 10o (4ZX4), 10q 
(4ZX5), 10s (4ZX6), and PfA-M17: 9b (4ZX8), 10b (4ZX9), 10o (4ZY2), 10q (4ZY0), 10r (4ZY1), 
10s (4ZYQ). 
4.4. Biology 
4.4.1. P. falciparum culture 
In vitro parasite culture of the P. falciparum strains 3D7, Dd2 and NITD609-R Dd2 clone#2 [28] 
were maintained in RPMI with 10 mM Hepes (Life Technologies), 50 µg/mL hypoxanthine (Sigma) 
and 5% Human serum from male AB plasma and 2.5 mg/mL AlbuMAX II® (Life Technologies). 
Human 0+ erythrocytes were obtained from the Australian Red Cross Blood Service (Agreement No: 
13-04QLD-09).  The parasites were maintained at 2-8 % parasitaemia (% P) at 5 % haematocrit (% H), 
incubated at 37 °C, 5 % CO2, 5 % O2, 90 % N2 and 95 % humidity. 
4.4.2. P. falciparum growth inhibition assay 
A well-established P. falciparum imaging assay was used to assess parasite growth inhibition [41].  
In brief, sorbitol (5% w/v) synchronisation was performed twice, approximately 8 h apart, on each 
synchronisation day for two consecutive ring cycles i.e. on day 1 and 3 of assay preparation.  On day 2 
the culture was split to approximately 2 % trophozoite parasitaemia.  On day 4 the culture was split to 
1-1.5% trophozoite parasitaemia, which yielded approximately 8% ring parasitaemia after 48 h on day 
5, the day of the assay setup. 
Compound stocks (10 mM in 100 % DMSO) were diluted 1 in 25 in H2O just prior to use.  An 
additional 1 in 10 dilution was performed, resulting in a 1:250 overall compound dilution and a final 
DMSO concentration of 0.4%.  For dose response curves a three step logarithmic serial dilution was 
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prepared at 20 µM top concentration for test compounds for the asexual assay and 2 µM for the positive 
control, artemisinin.  5 µL of the diluted test compound or control solutions (2 µM artemisinin as 
positive and 0.4% DMSO as negative control) were added to 384 well CellCarrier imaging plates 
(PerkinElmer).  Two biological replicates (each performed in duplicate) were performed for each 
compound (n=2). 
Parasite cultures were added to a final concentration of 2 % parasitemia and 0.3 % haematocrit.  
Plates were incubated for 72 h at 37 °C, 5 % CO2 and 95 % humidity.  On day 8 the permeabilization 
and nuclear staining buffer was prepared in PBS containing 10 µg/mL saponin, 0.01% triton X, 5 mM 
EDTA (all: Sigma) and 0.5 µg/mL 4′,6-diamidino-2-phenylindole (DAPI; Life Technologies) [41]. 
The plates were incubated at RT overnight, before confocal imaging on an Opera™ Confocal 
Imager (PerkinElmer) at 405 nm excitation with a 20x water objective.  Automated primary image 
analysis was performed concurrent with the imaging process, utilizing an Acapella® software 
(PerkinElmer) script to determine the number of parasites based on object size and fluorescence 
intensity [41].  Determination of the % growth compared to controls (2 µM artemisinin as positive and 
0.4% DMSO as negative control) was performed in Microsoft Excel® 2013.  Statistical analysis 
including IC50 determination and graphical output was performed in GraphPad Prism® 6 using 
nonlinear regression variable slope curve fitting. Representative growth inhibition and cytotoxicity 
curves of selected inhibitors can be found in Supp Fig 8. 
4.4.3. HEK293 viability assay 
To assess cytotoxicity of compounds in dose response, a resazurin-based assay was utilized to test 
for cell viability.  In brief, HEK293 cells were grown in DMEM medium (Life Technologies) 
containing 10% fetal calf serum (FCS; Gibco).  Cells were trypsinised, counted and seeded at 2000 
cells per well in 45 µL media into TC-treated 384-well plates (Greiner) and left to adhere overnight at 
37 °C, 5 % CO2 and 95% humidity. 
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Test compounds were prepared by diluting compounds 1 in 25 in sterile water and then another 1 in 
10 dilution, to give a top final test concentration of 40 µM, 0.4% DMSO.  Plates were incubated for 72 
h at 37 °C, 5% CO2 and 95 % humidity, then the media was removed and replaced by 35 µL of 44 µM 
resazurin in DMEM without FCS.  The plates were incubated for another 4-6 h at 37 °C, 5 % CO2 and 
95 % humidity, before reading on an EnVision® Plate Reader (PerkinElmer) using fluorescence 
excitation/emission settings of 530 nm/595 nm.  The % growth was standardized to controls (40 µM 
puromycin as positive and 0.4 % DMSO as negative control) using Microsoft Excel® 2013. Statistical 
analysis including IC50 determination and graphical output was performed in GraphPad Prism® 6 using 
nonlinear regression variable slope curve fitting. 
4.5. In Vitro ADME Studies 
4.5.1. LogD Measurement 
Partition coefficient values (LogD) of the test compound were estimated using a gradient HPLC 
based derivation of the method developed by Lombardo [42].  Data were collected using a Waters 2795 
HPLC instrument with a Waters 2487 dual channel UV detector (operated at 220 and 254 nm) with a 
Phenomenex Synergi Hydro-RP 4 µm (30 mm × 2 mm) column.  The mobile phase comprised aqueous 
buffer (50 mM ammonium acetate, pH 7.4) and acetonitrile with an acetonitrile gradient of 0% to 100% 
over 13.5 min.  Compound retention properties were compared to a set of nine standard compounds 
with known partition coefficients determined using shake flask methods. 
4.5.2. Solubility Estimation 
Kinetic solubility was determined by serial dilution of a concentrated stock solution prepared in 
DMSO, spiked into either pH 6.5 phosphate buffer or HCl (0.01 M, approx pH 2.0) with the final 
DMSO concentration being 1%.  Samples were then analysed via Nephelometry to determine a 
solubility range [43]. 
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4.5.3. In vitro Plasma Stability 
Human plasma (pooled; n=3 donors procured from the Australian Red Cross Blood Service) or mouse 
plasma (pooled; multiple mice procured from Animal Resources Centre, Perth) was separated from 
whole blood and stored frozen at -80°C.  On the day of the experiment, frozen plasma was thawed and 
an aliquot spiked with a DMSO/acetonitrile/water solution of test compound to a nominal compound 
concentration of 500 ng/mL (final DMSO and acetonitrile concentrations were 0.2 and 0.4% (v/v), 
respectively).  Spiked plasma was incubated at 37°C for 4 h (human) or 6 h (mouse), and at various 
time points, duplicate plasma samples were taken and immediately snap-frozen in dry ice.  All plasma 
samples were stored frozen (−20°C) until analysis by UPLC/MC (using a Waters/Micromass Quattro 
Premier triple quadrupole mass spectrometer coupled to a Waters Acquity UPLC) relative to 
calibration standards prepared in matched blank plasma.  At each sample time, the average 
concentration of test compound was expressed as a percentage remaining, and these data were used to 
calculate the apparent degradation half-life by fitting to an exponential decay function. 
4.5.4. In vitro Microsomal Stability 
Human or mouse liver microsomes (Xenotech, LLC, Lenexa, KS) were suspended in 0.1 M 
phosphate buffer (pH 7.4) at a final protein concentration of 0.4 mg/mL and incubated with test 
compound (1 µM) at 37°C.  An NADPH-regenerating system (1 mg/mL NADP, 1 mg/mL glucose-6-
phosphate, 1 U/mL glucose-6-phosphate dehydrogenase) and MgCl2 (0.67 mg/mL) was added to 
initiate the metabolic reactions, which were subsequently quenched with ice-cold acetonitrile at time 
points ranging from 0 to 60 min.  Samples were then subjected to centrifugation, and the concentration 
of parent compound remaining in the supernatant was monitored by LC-MS (Waters Micromass Xevo 
G2 QTOF coupled to a Waters Acquity UPLC).  The first order rate constant for substrate depletion 
was determined by fitting the data to an exponential decay function, and these values were used to 
calculate the in vitro intrinsic clearance that was scaled to predict the in vivo intrinsic clearance. 
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(4ZX6), and PfA-M17: 9b (4ZX8), 10b (4ZX9), 10o (4ZY2), 10q (4ZY0), 10r (4ZY1), 10s (4ZYQ). 
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Table 1 
Inhibition of PfA-M1 and PfA-M17 by hydroxamic acid compounds 9a-b, f-s and 10a-b, f-t. Ki 
values are the mean of three independent experiments. 
 
No. R1 R2 Ki (µM) 
PfA-M1 PfA-M17 
217 Boc pyrazole 0.85 0.028  
317 C(O)tBu pyrazole 0.72 0.028  
9a Boc F 5.3  1.7  
9b Boc Br 0.027  0.080  
9f Boc phenyl 37  0.055  
9g Boc 2-fluorophenyl 0.95  0.041  
9h Boc 3-fluorophenyl 0.95  0.13  
9i Boc 4-fluorophenyl 100  0.074  
9j Boc 2-(trifluoromethyl)phenyl 0.75  0.12  
9k Boc 3-(trifluoromethyl)phenyl 2.9  0.14  
9l Boc 4-(trifluoromethyl)phenyl >500 0.47  
9m Boc 3,4,5-trifluorophenyl 19  0.20  
9n Boc 3-pyridyl 1.1  0.22  
9o Boc 4-pyridyl 0.91  0.54  
9p Boc thiophen-3-yl 20  0.064  
9q Boc 1-methylpyraz-4-yl 1.9  0.056  
9r Boc 3-(amidoximo)phenyl 1.1  0.14  
9s Boc 4-(amidoximo)phenyl 0.40  0.018  
10a C(O)tBu F 4.0  0.029  
10b C(O)tBu Br 0.065  0.041  
10f C(O)tBu phenyl 1.6  0.007  
10g C(O)tBu 2-fluorophenyl 1.6  0.012  
10h C(O)tBu 3-fluorophenyl 0.55  0.0062  
10i C(O)tBu 4-fluorophenyl 6.5  0.033  
10j C(O)tBu 2,4-difluorophenyl 2.5  0.0052  
10k C(O)tBu 2,6-difluorophenyl 4.8  0.013  
10l C(O)tBu 3,4-difluorophenyl 1.4  0.0064  
10m C(O)tBu 3,5-difluorophenyl 0.58  0.092  
10n C(O)tBu 2,4,6-trifluorophenyl 5.9  0.0025  
10o C(O)tBu 3,4,5-trifluorophenyl 0.078  0.060  
10p C(O)tBu 2,3,4,5,6-pentafluorophenyl 1.8  0.0084  
10q C(O)tBu thiophen-3-yl 0.64  0.0091  
10r C(O)tBu 1-methylpyrazol-4-yl 11  0.0072  
10s C(O)tBu 3-(amidoximo)phenyl 5.4  0.0097  
10t C(O)tBu 4-(amidoximo)phenyl 4.3  0.0086  
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Table 2 
Inhibition of PfA-M1 and PfA-M17 by hydroxamic acid compounds 9c-e, t-u and 10c-e, u-v. Ki 
values are the mean of three independent experiments. 
 
No. R1 R2 Ki (µM) 
PfA-M1 PfA-M17 
9c Boc F 18  2.8  
9d Boc Br 39  7.7  
9e Boc I 4.3  21  
9t Boc phenyl > 500 5.2  
9u Boc 1-methylpyrazol-4-yl 120  14  
10c C(O)tBu F 63  0.037  
10d C(O)tBu Br 87  0.42  
10e C(O)tBu I 15  0.016  
10u C(O)tBu phenyl 27  0.65  
10v C(O)tBu 1-methylpyrazol-4-yl 39  0.74  
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Table 3 
Growth inhibition of cultured Pf by selected hydroxamic acid compounds 
 
 IC50 ± SEM (nM) IC50 ± SEM (nM) IC50 ± SEM (nM) 
 Pf-3D7 Dd2 Parent Dd2 SpiroR 
Artesunate 2.1 ± 0.2 1.3 ± 0.4 0.9 ± 0.3 
217 783 ± 87   
317 227 ± 4   
9b 293 ± 10   
9g 633 ± 24   
9q 978 ± 106   
9r 679 ± 33   
9s 334 ± 31   
10a 1530 ± 60 2010 ± 20 2090 ± 50 
10b 169 ± 17 194 ± 14 163 ± 45 
10f 96 ± 17 190 ± 12 219 ± 71 
10g 131 ± 5 207 ± 10 210 ± 25 
10h 162 ± 4 226 ± 10 316 ± 21 
10i 126 ± 4 225 ± 29 193 ± 7 
10j 109 ± 2 164 ± 46 216 ± 39 
10k 142 ± 17 251 ± 35 246 ± 34 
10l 139 ± 0.1 170 ± 52 195 ± 17 
10m 144 ± 0.0 239 ± 34 232 ± 43 
10n 125 ± 13 267 ± 47 450 ± 38 
10o 126 ± 2 189 ± 23 107 ± 20 
10p 130 ± 38 461 ± 42 408 ± 52 
10q 103 ± 3 110 ± 7 100 ± 5 
10s 469 ± 28 819 ± 48 627 ± 2 
10t 249 ± 23 303 ± 35 384 ± 8 
NC = No curve, activity not sufficient to fit curve to data. 
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Table 4 
Solubility and stability characteristics of 10o. 
 
Parameter Value 
Solubility (µg/mL)a 
    pH 2 
  pH 6.5 
 
12.5–25 
12.5–25 
LogDpH 7.4b 3.0 
Stability in Liver Microsomes 
  Mouse: t1/2 (min) / CLint (µL/min/mg protein) 
  Human: t1/2 (min) / CLint (µL/min/mg protein) 
 
69 / 25 
221 / 8 
Plasma Stabilityc 
  Mouse : t1/2 (h) 
  Human : t1/2 (h) 
 
 
>25 
>17 
a Kinetic solubility determined by nephelometry   
b Value measured by the chromatographic LogD technique.  
c No measureable degradation 
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Fig. 1. Solvent accessible surface diagrams of the active sites of PfA-M1 
(A) and PfA-M17 (B). Positions of active site residues, catalytic zinc ions, 
and, for PfA-M17, catalytic carbonate ions, are shown. (C) ((4-(1H-
Pyrazol-1-yl)phenyl)(amino)methyl)phosphonic acid [16] (1), tert-butyl 
(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-oxoethyl)carbamate 
[17] (2) and N-(1-(4-(1H-pyrazol-1-yl)phenyl)-2-(hydroxyamino)-2-
oxoethyl)pivalamide [17] (3). 
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Fig. 2. Binding pose of hydroxamic-acid inhibitors to PfA-M1 (grey cartoon) and PfA-M17 
(wheat cartoon). A and B, Overlay of 9b (grey sticks) with 10b (green sticks) when bound to 
PfA-M1 (A) or PfA-M17 (B). Interactions between the tert-butyl containing moieties (N-Boc in 
9b and N-pivaloyl in 10b) and binding pocket residues are shown as dashed lines in grey (9b) or 
green (10b). C and D, Compound 10b (green sticks) bound to PfA-M1 (C) and PfA-M17 (D). 
Interactions formed between the hydroxamic acid and S1-binding scaffold with the active sites 
are shown as dashed lines. Interactions between the S1’ anchor and the binding sites are not 
shown. E, Interactions formed between the biphenyl substituent of 9f (blue) and PfA-M1. Cα 
chain shown for PfA-M1 active site helix when 9b (green chain) and 9f (grey chain) are bound. 
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Fig. 3. Binding of pivalamide series to PfA-M1 (grey) and PfA-M17 (wheat). A, Interactions 
between the substituted biaryl of 10o (orange sticks) and PfA-M1 (grey). Fluorine-hydrogen-
bonds shown as orange dashed lines and hydrophobic interactions shown as black dashed lines. 
B, Shifted binding pose of 10q (teal) when bound to PfA-M1 (shown as grey surface) 
compared to 10o (orange) and 9f (blue). C, Interactions between the biphenyl system of 10q 
(teal) and PfA-M1 (grey), shown as black dashed lines. D, dual binding pose of 10s (pink) 
when bound to PfA-M1. Disordered residues shown as red sticks. E, Compounds 10o (orange), 
10q (teal) and 10s (pink) bound to PfA-M17 (wheat). Active site methionine residue M392 
(stick representation, coloured according to inhibitor bound) is observed to shift in and out of 
the pocket depending on interactions with compound. F, Interactions between the substituted 
biaryl of 10o (orange sticks) and PfA-M17 (wheat). Fluorine-hydrogen-bonds are shown as 
orange dashed lines and hydrophobic interactions shown as black dashed lines. 
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Scheme 1.  a Reagents and conditions: (a) i. cat. concd H2SO4, MeOH, reflux; ii. Boc2O, THF, water, rt, 
or pivaloyl chloride, Et3N, DCM, rt; (b) i. Boc2O, 2M NaOH (aq), THF, water; ii. CDI, dry THF, rt; iii. 
NH2OH.HCl; (c) i. dry MeOH, rt; ii. NH2OH.HCl, 5M KOH/MeOH, dry MeOH (premixed), rt; (d) cat. 
PdCl2(PPh3)2, boronic acid or boronate ester, degassed 1M Na2CO3 (aq), degassed THF, 100 °C. 
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RESEARCH HIGHLIGHTS: 
• Dual inhibition of PfA-M1 and PfA-M17 is proposed as a novel antimalarial strategy. 
• Compound series containing hydroxamic acid zinc binding group optimized by SBDD. 
• Compounds elaborated into S1 pockets of PfA-M1 and PfA-M17. 
• Optimized compounds possess superior PfA-M1 and PfA-M17 inhibitory activity. 
• The potent, dual inhibitors inhibit multi-drug resistant Pf growth in culture. 
